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HIV-1 capsid engages nucleoporin NUP153 to promote viral nuclear entry 
 
Abstract 
Lentiviruses can infect non-dividing cells, and various cellular nuclear transport 
proteins provide crucial functions for lentiviral nuclear entry and integration. Genome-
wide small interfering RNA screens previously identified nuclear pore complex 
component nucleoporin 153 (NUP153) as being important for infection by human 
immunodeficiency virus type 1 (HIV-1). We found that HIV-1 infection of NUP153 
depleted cells resulted in normal levels of reverse transcription, a moderate reduction of 
2-long terminal repeat circles, and a relatively large reduction in integrated proviruses, 
consistent with a role for NUP153 during nuclear entry of the HIV-1 pre-integration 
complex. We ascertained the capsid (CA) to be the major viral determinant for NUP153 
dependence during infection, and accordingly observed a direct interaction between the 
CA N-terminal domain and the phenylalanine-glycine (FG)-repeat enriched NUP153 C-
terminal domain (NUP153C). NUP153C fused to the effector domains of the rhesus 
Trim5 restriction factor (Trim-NUP153C) potently restricted HIV-1, providing an 
intracellular readout for the NUP153C-CA interaction during retroviral infection. Primate 
lentiviruses and equine infectious anemia virus (EIAV) bound NUP153C under these 
conditions, results that correlated with direct binding between purified recombinant 
proteins in vitro. These binding phenotypes moreover correlated with the requirement for 
endogenous NUP153 function during infection. Mutagenesis experiments identified 
 iv 
NUP153C and CA residues important for binding, and different FG motifs within 
NUP153C mediated binding to HIV-1 versus EIAV CA proteins. HIV-1 CA binding 
mapped to residues that line a common alpha helix 3/4 hydrophobic pocket that also 
mediates binding to the small molecule PF-3450074 (PF74) inhibitor and cleavage and 
polyadenylation specific factor 6 (CPSF6) protein, with Asn57 (Asp58 in EIAV) playing 
a particularly important role. PF74 and CPSF6 each competed with NUP153C for binding 
to HIV-1 CA, and significantly higher concentrations of PF74 were needed to inhibit 
HIV-1 infection in the face of Trim-NUP153C expression or NUP153 knockdown. 
Correlation between CA mutant viral cell cycle and NUP153 dependencies moreover 
indicated that the NUP153C-CA interaction underlies the ability of HIV-1 to infect non-
dividing cells. We propose that HIV-1 CA binds NUP153 FG motifs to affect viral 
nuclear import, serving as a novel example of viral hijacking of a fundamental cellular 
process. 
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The HIV-1 replication cycle 
 Human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired 
immunodeficiency syndrome (AIDS) [1-3]. HIV/AIDS remains a global pandemic with ~ 
34 million individuals infected as of 2010, and the virus was estimated to have caused ~ 
1.8 million deaths in that same year [4]. There are currently no effective prophylactic or 
therapeutic vaccines for HIV-1 infection. Although the development of combined anti-
retroviral therapy regimens have curtailed AIDS progression in HIV infected individuals 
in developed nations, these treatments are not widely available in either Sub-Saharan 
Africa or South and Southeast Asia, which are experiencing the greatest disease burden. 
 Aside from its epidemiological relevance, HIV-1 is the prototypical lentivirus, 
and provides a common model to understand the molecular processes undertaken by 
viruses of the family Retroviridae. Like all viruses, HIV-1 must initiate its replication 
cycle by first gaining entry into the target cell (Figure 1-1). HIV-1 initiates viral entry by 
binding the cell surface protein CD4 [5], which is expressed to high levels on a number 
of immune cells, including CD4 positive subsets of T-lymphocytes, macrophages, and 
dendritic cells. This binding event triggers conformational changes in the viral envelope 
protein, revealing its site for co-receptor binding. Binding to an HIV-1 co-receptor, most 
commonly proteins CCR5 [6-10] or CXCR4 [11-13], triggers a cascade of events 
resulting in the fusion of the viral and cellular membranes, releasing the viral core into 
the cell cytoplasm. 
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Figure 1-1. Schematic of the HIV-1 replication cycle. HIV-1 infection is initiated when the 
virion binds to receptor molecules on the target cell, which triggers fusion between the viral and 
cellular membranes (Entry). Reverse transcriptase (RT) housed within the capsid core then 
creates a double stranded DNA templated by the viral RNA genome (Reverse transcription). 
Upon trafficking into the nucleus, the viral DNA is integrated into a host chromosome by the 
viral integrase (IN) protein (Integration). This completes the first half of the HIV-1 replication 
cycle. The integrated provirus is next transcribed by host RNA polymerases to yielded viral 
transcripts (Transcription), which are alternatively spliced and later translated to create the 
various viral protein products (Translation). Unspliced genomic RNA, along with the viral 
structural proteins, traffick to sites of virion assembly at the plasma membrane (Assembly). Here, 
the developing virion buds from host membrane and releases (Budding). Lastly, the nascent HIV-
1 particle must undergo a maturation step to form a fully infectious virion (Maturation). The viral 
particle is now ready to find its next target cell to begin a new round of its replication cycle. 
 
5 
While in the cytoplasm, HIV-1 reverse transcribes its genome, creating a double-
stranded DNA templated by the RNA genomes packaged within its core [14]. 
Retroviruses such as HIV-1 differ from other animal viruses by requiring integration into 
host chromosomes as an obligate step of their life cycles. Accordingly, upon trafficking 
into the nucleus, the double stranded viral DNA is inserted into a host chromosome by 
the viral IN protein [15-17]. Once integrated, the virus is transcribed by host RNA 
polymerase II. The resulting RNA molecules are either left intact or alternatively spliced 
to yield blueprints for the full complement HIV-1 viral proteins [18]. Once translated, the 
resulting protein products assemble with the unspliced viral genomic RNA at the plasma 
membrane [19]. The viral particle buds from the plasma membrane until it completes its 
assembly process and releases [20]. After release, the HIV-1 protease (PR) cleaves the 
intravirion components of the immature virion, in a process termed maturation . The 
mature virion, now exhibiting the classical conical core morphology associated with HIV, 
is now fully infectious and ready to embark on another round of infection. 
 
General retroviral strategies for nuclear entry 
Although many of the molecular mechanisms that govern the steps of the 
replication cycle are now well characterized, the molecular processes HIV-1 undertakes 
to gain access to the host chromosomes are not well understood. Aside from the periods 
of time when animal cells are actively dividing, cell chromosomes and the associated 
nucleoplasm are separated from the cytoplasm by two sets of adjoining membranes, 
together referred to as the nuclear envelope. Seven retroviral genera, including α through 
ε, lenti-, and spuma-, comprise Retroviridae. The γ-retrovirus Moloney murine leukemia 
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virus (MLV) and lentivirus HIV-1 are historic model systems for the study of retroviral 
nuclear import due to their contrasting dependencies on the cycling state of the cells that 
they infect. MLV is highly dependent on cellular mitosis, and accordingly requires the 
dissolution of the nuclear envelope to gain access to host chromosomes [21]. 
Contrastingly, HIV-1 productively infects post-mitotic cell types [22], and accordingly 
possesses a mechanism to bypass an intact nuclear envelope to gain access to host 
chromosomes. 
 
The classical mechanism of protein import through the nuclear pore 
HIV-1 nucleoprotein complexes are believed to enter the nucleoplasm by passing 
through nuclear pore complexes (NPCs), which stably perforate the nuclear envelope 
during interphase and gate-keep the trafficking of molecules between the cell nucleus and 
cytoplasm (Figure 1-2). Each NPC is composed of ~ 30 different protein constituents 
called nucleoporins (NUPs) [23,24], which are found in various multiples of 8 to yield 
the ~ 120 MDa tubular structures found in animal cells [25]. Transport through the NPC 
is highly selective; molecules less than ~ 9 nm in diameter are able to passively diffuse 
through the channel, while those up to ~ 39 nm must be actively transported by 
interacting with specific carrier proteins [26]. Protein cargos are most often imported by 
members of the karyopherin (KPN) β superfamily [27]. These proteins pass through the 
pore by interacting with phenylalanine-glycine (FG) motifs that are found in highly 
flexible domains present in about one-third of the NUPs and line the inner channel of the 
NPC structure. Though the precise biophysical mechanism of nuclear transport is not  
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Figure 1-2. Schematic of the NPC and classical nuclear import pathway. (top) General NPC 
substructures and locations of NUPs that scored as potential HIV-1 co-factors in genome-wide 
RNA interference (RNAi) screens [28-31]. Asterisks denote NUPs that scored in more than one 
screen. (bottom) The Ran-based nuclear import cycle. Import protein cargo binds to a KPN β 
protein, oftentimes bridged by a member of the KPN α protein family (KPN β1, which is also 
referred to as importin β1, and KPN α2 or importin α1, depicted, are canonical members of each 
protein family). KPN β1 ferries the complex through the NPC channel. The engagement of KPN 
β1 by Ran-GTP concentrated at the nuclear basket releases the KPN α-cargo complex into the 
nucleus. KPN β1 becomes free to bind additional import cargo after Ran dissociates from it upon 
RanBP1 binding and Ran-GTP hydrolysis, stimulated by RanGAP concentrated at the 
cytoplasmic filaments. 
 
 
8 
completely understood, it is clear that transport is largely dictated by the properties 
exerted by these FG-containing domains [32]. 
Directionality of nuclear translocation is governed by the gradient of the small 
Ras-related nuclear (Ran) GTPase protein, which is established through the asymmetric 
distribution of two Ran co-factors on opposite sides of the nuclear envelope (Figure 1-2). 
Regulator of chromosome condensation (RCC) 1, which is also referred to as Ran 
guanine nucleotide exchange factor (RanGEF), achieves nuclear compartmentalization 
through its association with nucleosomes [33], while Ran GTPase activating protein 
(RanGAP) is found associated with NUP358 filaments emanating from the cytoplasmic 
face of the NPC [34]. The classical mechanism of protein nuclear import is governed by 
two features: Ran binds KPN β proteins when it is complexed with guanosine 
triphosphate (GTP) rather than guanosine diphosphate (GDP), and protein cargos 
undergoing nuclear import preferentially bind Ran-free KPN β proteins. Due to the Ran 
gradient, KPN β proteins bind their import cargos within the cytoplasm, and ferry their 
cargos through the nuclear pore by interacting with the FG barrier [35]. Once in the 
nucleus, abundantly present RanGTP binds the KPN β protein, freeing the protein cargo 
within the nucleus. RanGTP-bound KPN β proteins are able to transit back into the 
cytoplasm, where Ran binding protein (RanBP) 1 and RanGAP stimulate the conversion 
of RanGTP to RanGDP [36] and dissociate Ran from the KPN β protein, completing the 
import cycle. Protein nuclear export cargos differ by preferentially binding RanGTP-
bound carrier proteins, such as exportin (XPO) 1, to form ternary complexes that are 
released into the cytoplasm when Ran is freed upon binding with RanBP1/2 [37,38]. 
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The HIV-1 substrate for nucleocytoplasmic transport 
Mature HIV-1 virions harbor a relatively full complement of viral proteins, 
including gag- (matrix, MA; capsid, CA; nucleocapsid, NC; p6) and pol- (PR; RT; IN) 
encoded proteins, as well as a handful of accessory proteins (Vif, Vpr, and Nef). CA is 
composed of two independently folded protein domains, the N-terminal domain (NTD) 
and C-terminal domain (CTD), which are separated by a flexible linker [39]. During 
particle maturation, approximately one-half of the complement of CA protein condenses 
into a conical shell that is predominantly comprised of hexameric CA rings; twelve 
pentameric rings afford shape declinations necessary to enclose retroviral CA shells [40-
43]. The mature core shell encases the viral components that are necessary to complete 
the early steps of retroviral infection, which includes the two copies of the viral RNA in 
complex with NC, RT, and IN. The viral core undergoes its first step in a series of 
conformational and compositional changes that occur following its entry into the 
cytoplasm, when the virus begins to reverse transcribe its genome in the context of a 
subviral complex commonly referred to as the reverse transcription complex (RTC) 
(Figure 1-3) [44]. DNA synthesis likely triggers CA shell disassembly, as prevention of 
reverse transcription can delay the steps of core uncoating [45]. As the CA core begins to 
disassemble, some viral proteins diffuse away from the now permeable CA shell [46]. 
The combination of CA core disassembly and additional host-protein recruitment 
increases the size of the RTC to an estimated ~ 100-250 nm in diameter [47-49]. The 
number of complete, or near-complete reverse transcribed genomes in a population of 
infected cells can be readily measured by quantitative PCR, most commonly with a 
primer pair that generates an amplicon spanning from the upstream long terminal repeat  
10 
 
 
 
 
 
 
 
 
Figure 1-3. PCR-based methods for detection of post-entry to viral DNA integration steps of 
HIV-1 infection. (A) Generalized replication intermediates and byproducts leading up to 
integration. (B) Order of viral trafficking and RT and IN enzymatic steps. (C) Summary of viral 
DNA species that serve as markers for the various infection intermediates and byproducts. 
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(LTR) to a sequence past the primer binding site, such as a sequence in the upstream 
region of the gag gene; the viral DNAs detected by such reactions are commonly referred 
to as late reverse transcription (LRT) products because they depend on the second 
template switch of reverse transcription for their formation [50,51]. Once reverse 
transcription is completed, IN hydrolyzes the extremities of the linear viral DNA adjacent 
to conserved cytosine-adenine dinucleotides located within the viral LTRs to generate 
reactive CAOH-3’ ends [52,53]; the resulting 3’-hydroxyl groups are subsequently used by 
IN to cut target DNA to effect viral DNA joining [54]. By convention, the integration-
competent nucleoprotein complex formed by IN 3’ processing activity is referred to as  
the preintegration complex (PIC). These preceding steps are believed to largely occur 
within the cytoplasm, as the virus traffics to the nuclear periphery along microtubules 
[49]. 
 
Techniques for measurement of HIV-1 nuclear import 
The majority of HIV-1 particles are noninfectious [55], and it is accordingly 
challenging to observe HIV-1 PIC nuclear transport directly with certainty. Nuclear 
transport is routinely inferred through comparison of steady-state levels of readily 
detectable markers of the bulk infection (Figure 1-3). Arguably, the most direct method 
is quantitative assessment of LRT DNA in cytoplasmic versus nuclear fractions. 
Importantly, this requires careful validation of the fidelity of fractionation, using control 
protein or nucleic acid markers appropriate to represent the separate compartments 
[56,57]. While many fractionation procedures likely separate soluble cytoplasmic 
components adequately, protocols likely differ in their abilities to distinguish 
12 
nucleoplasmic viral DNA from PICs associated with the NPC, or strongly associated with 
the cytoskeleton. Before successfully integrating into a host chromosome, a subset of 
PICs [58] are instead diverted to form non-productive DNA products through the action 
of host cell-mediated DNA repair pathways: 1-LTR circles can be produced by 
homologous recombination [59] or from aberrant reverse transcription [60,61], while 2-
LTR circles are formed through non-homologous end joining of the viral DNA [62]. PCR 
primers that amplify products that span the LTR-LTR circle junction provide a 
convenient, albeit indirect measurement for assessing the competence of the virus to 
reach the nuclear interior [61]. Due to the generation of reactive CAOH ends by IN 3’ 
processing activity, a fraction of PICs aberrantly integrate their LTR ends back into an 
internal region of the viral DNA in a process referred to as autointegration [63-66]. 
Importantly, autointegrants formed by the insertion of one LTR end in the vicinity of the 
second viral DNA end can score as positive in assays quantitating 2-LTR circles, 
confounding the use of 2-LTR circle measures as readouts for nuclear viral DNA [66]. 
Specific aspects of PCR design, which take into account the DNA sequence at the LTR-
LTR circle junction, can accordingly help to mitigate this complication [66]. Absolute 
and relative levels of integration can be measured through PCR reactions specific for 
integrated proviral DNA [51,67], while the distribution of integration sites along 
chromosomes are assessed by identifying sequences of viral-cellular DNA junctions 
within the infected cell population [68,69]. Although continuous advancement of various 
microscopy-based approaches provides an important additional avenue to assess HIV-1 
nuclear import and integration [48,70,71], high-throughput, live-cell approaches capable 
of kinetically witnessing individual nuclear import events are not yet available. 
13 
Various biochemical approaches have yielded insight into the viral proteins that 
remain as part of the viral nucleoprotein substrate for nuclear import. The RTC/PIC 
observed in the cytoplasm exceeds the diameter of the pore [48,49], so only a fraction of 
the viral and cellular proteins that associate with the PIC in the cytoplasm likely enter the 
nucleus [48]. The double-stranded reverse-transcribed viral DNA and a tetramer of IN 
protein form the heart of the PIC, as they comprise the intasome nucleoprotein complex 
that drives integration [72,73]. Keeping in mind that only one functional PIC is formed 
per infectious event, the identities of other PIC-associated viral proteins have been 
difficult to identify precisely. MA, RT, and Vpr were repeatedly found to be components 
of viral nucleoprotein complexes isolated from nuclear fractions [56,74-77]. A handful of 
studies found NC and PR as well [75,76,78], while CA was noticeably absent from many 
of these same studies [56,74-78]. In fact, CA was either observed to be absent [44,77], or 
found in only scant amounts [79] within viral complexes extracted from whole-cell or 
cytoplasmic extracts, prompting initial belief that the HIV-1 core uncoats completely 
prior to PIC formation. Subsequent microscopy studies have more readily observed CA 
in association with cytoplasmic nucleoprotein complexes [48,49,80], though the duration 
of this association remains largely unknown. While some studies have detected CA in the 
nuclear fraction following HIV-1 infection [81,82], it is not entirely clear how much of 
this signal represents intranuclear CA rather than CA protein associated with the nuclear 
envelope. It would therefore be instructive to determine how much of this signal co-
fractionates with nuclear PICs. 
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Viral and cellular elements implicated in HIV-1 PIC nuclear import 
Many of the viral elements found in association with the PIC have been proposed 
to be important for HIV-1 nuclear import. Nuclear localization signals (NLSs) present in 
MA [83,84] and IN [76,85], as well as various non-canonical karyophilic signals in Vpr 
[77,86-90], have each been proposed to recruit cellular nuclear transport proteins. Basic-
type NLSs within IN have been proposed to recruit KPN α adaptor proteins importin α1 
(Rch1) [76] and importin α3 (KPNA4) [91], which would presumably require additional 
binding to KPN β1 for function (Figure 1-2). IN can also directly interact with KPN β 
proteins importin 7 [92,93] and transportin 3 (TNPO3, TRN-SR2, or importin 12) 
[70,94], though the relevance of these interactions have been brought into question [95-
97]. IN and Vpr are additionally proposed to bind NUPs directly to facilitate nuclear 
import without the need for adaptor KPN carrier proteins, which include interactions 
between IN and NUP153 [98], and Vpr with Pom121 [86] or hCG1 [99]. 
The reverse transcribed genome is suggested to be an important determinant of 
HIV-1 PIC nuclear import, primarily through a triple stranded DNA flap element 
generated through the action of the central polypurine tract (cPPT) and central 
termination signal (CTS) [100,101]. While this element is not absolutely required for 
either nuclear import or infection [102-104], numerous groups have confirmed that the 
DNA flap exerts a positive effect during infection [105-107]. DNA plus-strand extension 
from the cPPT primer likely decreases the overall duration of reverse transcription within 
the cell [106,108], which may indirectly influence viral nuclear import during instances 
of limiting nucleotide concentrations, for example. Such a kinetic advantage to reverse 
transcription conferred by the cPPT is consistent with its ability to reduce the time-frame 
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in which the viral single-stranded DNA is sensitive to the inhibitory activity of 
APOBEC3 cytosine deaminase restriction factors [109-111], and may similarly protect 
the RTC/PIC from other host defense proteins that could derail its trafficking. 
While HIV-1 MA, IN, and Vpr NLSs can confer nuclear localization when fused 
to otherwise cytoplasmic proteins, some studies have refuted the importance of these 
signals in PIC nuclear import during infection [103,106,112-114]. Various features of 
HIV-1 biology can help to explain some of these discrepancies. Firstly, MA and IN in 
particular are not known to function as free proteins during the early phase of HIV-1 
infection. Thus, studying MA or IN as recombinant proteins expressed in human cells 
may not uncover behaviors relevant to PIC biology. Secondly, many of the viral 
constituents of the PIC are multifunctional proteins, whereby mutations may result in 
multiple coincident defects to infection, obfuscating the targeted assessment of 
contributions to a particular phenotype. Lastly, there is little evidence to support that 
HIV-1 enters the nucleus during mitosis when its passage through the NPC is blocked 
[115]. Thus, the historical perspective that HIV-1 nuclear import mutants would 
specifically be blocked for infection of non-dividing target cell types would since appear 
to be largely misguided. 
 
CA functionally determines requirements for nuclear trafficking 
The field has more recently moved to view CA as the major viral protein that 
mediates HIV-1 nuclear import. Masahiro Yamashita and Michael Emerman 
demonstrated that infection by an HIV-1 chimeric virus that carried the MLV CA protein 
was cell cycle dependent [116], mimicking the property of parental MLV. The defect to  
16 
 
 
 
 
 
 
 
 
 
Figure 1-4. Schematic of HIV-1 CA and mutations. A single HIV-1 CA monomer (protein 
database code 3j34) is represented by a cartoon of the peptide backbone, as well as a semi-
transparent surface: NTD, green; flexible linker, purple; CTD, red. A subset of CA residue side-
chains that exhibit phenotypic differences in preintegrative steps of HIV-1 infection are shown as 
sticks and colored as follows: carbon, orange; nitrogen, blue; oxygen, red 
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infection upon cell cycle arrest was at the step of nuclear import, as a decrease in the 
formation of 2-LTR circle DNAs relative to wild-type (WT) HIV-1 was observed [116]. 
They subsequently determined that certain point mutations in HIV-1 CA, including 
T54A/N57A and Q63A/Q67A (Figure 1-4), also imparted cell cycle dependence to HIV-
1 [57]. Notably, the infection defect exhibited by the T54A/N57A mutant virus upon cell 
cycle arrest occurred after nuclear entry but before integration [57]. While this mutant 
was sensitive to cell cycle arrest in all cell lines tested, the growth arrest phenotypes of 
A92E and G94D CA mutant viruses, which are hypersensitive to the levels of CA-
interacting host protein cyclophilin A (CypA) in certain cell lines (Hela and H9 cells), 
were restricted to these same cells [117,118]. Cell cycle arrest also inhibited these viruses 
after nuclear import, as both LRT and 2-LTR circle levels remained unchanged. While 
the infection defects experienced by these CA mutant viruses upon cell cycle arrest occur 
following HIV-1 nuclear entry, the Q63A/Q67A mutant virus appeared to be defective 
for nuclear import, as it exhibited decreased levels of 2-LTR circle formation as 
compared to WT virus in dividing cells [119]. Q63A/Q67A CA cores recovered from 
whole virions following detergent treatment were less stable than WT cores in vitro 
[120], but the mutant viral RTCs and PICs retained a greater complement of CA protein 
than did the WT virus during infection [45,57,119]. This apparent delay in Q63A/Q67A 
core uncoating appears related to the nuclear import and integration defects experienced 
by this mutant virus. 
A number of additional CA-interacting host factors have been observed to affect 
HIV-1 nuclear import and integration. The rhesus Trim5α restriction factor normally 
restricts HIV-1 infection by targeting the viral core for disassembly and degradation prior 
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to the completion of reverse transcription [121,122]. Inhibition of cellular proteasome 
activity with the small molecule MG132 rescued reverse transcription while having no 
effect on the ultimate level of integration [123]. The MG132-rescued RTCs seemingly 
remain intact [124] and mature into integration-competent PICs [125]. These complexes 
also escape entrapment by proteasome-associated cytoplasmic bodies [126] yet 
accumulate fewer 2-LTR circles, consistent with a trafficking defect coincident with or 
shortly prior to nuclear import [123,125]. Various artificially engineered Trim-CypA 
fusion constructs have also been shown to cause defects to infection after reverse 
transcription, though these appear to occur after nuclear entry [127]. 
Perturbation of CA can also affect the post-reverse transcription steps of other 
retroviruses. Though MLV does not enter the nucleus via the NPC, it must also in large 
part dissolve its CA shell to effect IN-mediated integration. MLV CA is readily found in 
RTCs purified from infected cells, and remains stably associated with the PIC until it 
enters the nucleus [128]. MLV p12, a gag-encoded protein not found in HIV-1, is crucial 
for nuclear targeting as it tethers PICs to mitotic chromosomes [129-131]. While MLV 
CA dissociates from the PIC during mitosis, p12 mutants PM14 and S61A/S65A, which 
are defective for mitotic chromosomal tethering, each maintain CA in association with 
the PIC during mitosis [132]. Certain murine cells take advantage of RTC/PIC-associated 
CA to interrupt the MLV infection mechanism: the protein expressed from Friend virus 
susceptibility-1 (Fv1), which is a gag-related gene from a murine endogenous 
retroelement [133], is able to target MLV cores to inhibit infection [134-136]. Restricted 
MLV still reverse transcribes and forms PICs capable of integrating in vitro [137], yet 
does not form circular DNA byproducts [138,139]. The product of the Fv1 gene can also 
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inhibit HIV-1 infection when targeted to HIV-1 CA upon fusion to CypA, resulting in a 
quantifiable decrease in the number of integrated proviruses while leaving the 
accumulation of 2-LTR circles unchanged [140]. 
Together, these results show that the retroviral core shell is unlikely to passively 
fall apart upon viral entry, but instead functions at a critical juncture bridging reverse 
transcription and nuclear trafficking. Although premature CA disassembly and 
proteasomal targeting may exert their effects as early as reverse transcription, other 
perturbations to CA uncoating and CA-determined trafficking defects prevent PIC 
nuclear import, or even manifest as defects within the nucleus. MLV has specifically 
evolved to access chromosomes during mitosis, and accordingly, the combined functions 
exerted by MLV CA and p12 likely specifically link MLV uncoating and nuclear entry 
with mitosis. In the aforementioned chimeric HIV-1 encoding MLV gag, the PIC is likely 
forced into an MLV-type mechanism of nuclear entry. Contrastingly, the cell cycle 
dependence of HIV-1 CA missense mutations may be due to reasons stemming from 
various potential losses in function: for example, perturbed core engagement with host 
proteins may result in a virus blocked at one of many preintegrative steps of infection, 
and may require cellular rearrangements that occur during cell division to relieve this 
block. While the previously described phenotypes affecting CA reveal the effects the 
retroviral core may exert on the steps following reverse transcription, recent findings that 
CA protein physically associates with nuclear transport factors hints that CA takes a 
direct role in promoting the nuclear steps of HIV-1 infection. 
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RNA interference screens highlight specific nuclear transport proteins as HIV-1 
host factors 
A series of genome-wide RNAi screens [28-31] identified numerous nuclear 
transport factors as potential HIV-1 cofactors: TNPO3, NUP358/RANBP2, NUP155, 
NUP153, and NUP98 were each identified in two independent screens, while a number of 
additional NUPs (NUP50, NUP62, NUP85, NUP107, NUP133, NUP160, NUP210, 
NUP214, ELYS, and TPR) and soluble transporters (KPN β1, XPO1, and NXF1) each hit 
once [28-31,141] (Figure 1-2). The HIV-1 requirement for TNPO3, NUP358, and 
NUP153 were initially mapped to the nuclear steps of infection, either preceding or 
concomitant with integration [29]. 
TNPO3 (also referred to as Transportin-3 or Transportin-SR2) is a soluble 
transport receptor belonging to the KPN β superfamily. TNPO3 is responsible for the 
nuclear import of a subset of serine/arginine-rich host proteins required for pre-mRNA 
splicing, termed SR-proteins [142]. NUP358 (also referred to as RanBP2) is a large NUP 
that forms the cytoplasmic filaments which emanate from the cytoplasmic side of the 
nuclear pore complex [143-145]. The domains of this protein are involved in many 
different cellular functions: Ran-binding domains and FG repeats involved in controlling 
nucleocytoplasmic transport [146], zinc fingers required for nuclear envelope breakdown 
during mitosis [147], a SUMO E3 ligase domain necessary for sumoylation-based protein 
targeting [148], various domains for interacting with kinesins and microtubules to 
mediate organelle interaction with the cytoskeleton [149,150], and a C-terminal CypA 
homologous domain (CHD) likely involved in protein isomerization [151-153]. 
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Nucleoporin NUP153 is a potential HIV-1 cofactor for HIV-1 PIC trafficking 
My work has focused on NUP153, which is a relatively large (1475 amino acid) 
NUP found on the nuclear side of the NPC [154]. Its NTD is important for its localization 
and its functions in NPC scaffolding: it houses a nuclear localization signal [155], and it 
has separate regions involved in nuclear envelope binding [156], as well as protein 
interactions with nucleoporins NUP160, NUP50, and TPR [157-159]. Its central zinc-
fingers bind Ran [160], but also recruit COPI for nuclear envelope breakdown during 
mitosis [147,161]. Most interestingly, NUP153 possesses a long, highly flexible CTD 
which reaches into the central channel [162] and can extend across to the cytoplasmic 
side of the NPC in a transport-dependent manner [163-165]. This domain contains 29 FG 
motifs of the patterns FG, FxF, or FxFG, and is involved in the nucleocytoplasmic 
transport of a variety of protein or nucleoprotein cargos [166,167]. 
In this thesis, I describe our investigation of the role of NUP153 during the 
process of HIV-1 ingress, particularly the postentry steps leading up to viral integration. I 
found that a direct interaction between the NUP153 FG motifs and the HIV-1 capsid 
protein underlie the viral requirement for NUP153 during its nuclear import, serving as a 
novel example of viral hijacking of a key feature of cellular nucleocytoplasmic transport. 
I propose that similar mechanisms of direct binding between viral capsids and host cell 
phenylalanine-glycine motifs extends to additional retroviruses, and may even extend to 
additional viral families.
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Chapter 2 
 
Human Immunodeficiency Virus Type 1 (HIV-1) Capsid Determines the 
Requirement for Cellular NUP153 during a Nuclear Step of HIV-1 Infection 
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Abstract 
 
Lentiviruses likely infect nondividing cells by commandeering host nuclear transport 
factors to facilitate the passage of their PICs through NPCs within nuclear envelopes. 
Genome-wide small interfering RNA screens previously identified karyopherin β 
transportin-3 (TNPO3) and NPC component NUP153 as being important for infection by 
HIV-1. The knockdown of either protein significantly inhibited HIV-1 infectivity, while 
infection by the gammaretrovirus MLV was unaffected. Here, we establish that primate 
lentiviruses are particularly sensitive to NUP153 knockdown and investigate HIV-1-
encoded elements that contribute to this dependency. Mutants lacking functional Vpr or 
the central DNA flap remained sensitive to NUP153 depletion, while MLV/HIV-1 
chimera viruses carrying MLV MA, CA, or IN became less sensitive when the latter two 
elements were substituted. Two CA missense mutant viruses, N74D and P90A, were 
largely insensitive to NUP153 depletion, as was WT HIV-1 when CypA was depleted 
simultaneously or when infection was conducted in the presence of cyclosporine A. The 
codepletion of NUP153 and TNPO3 yielded synergistic effects that outweighed those 
calculated based on individual knockdowns, indicating potential interdependent roles for 
these factors during HIV-1 infection. Quantitative PCR revealed normal levels of late 
reverse transcripts, a moderate reduction of 2-LTR circles, and a relatively large 
reduction in integrated proviruses upon NUP153 knockdown. These results suggest that 
CA, likely by the qualities of its uncoating, determines whether HIV-1 requires cellular 
NUP153 for PIC nuclear import. 
25 
Introduction 
 
The early steps of the retroviral life cycle occur within the context of nucleoprotein 
complexes that are derived from the core of the infecting viral particle. The RT enzyme 
converts genomic RNA into linear double stranded viral DNA (vDNA) within the 
confines of the RTC [44,128]. Soon thereafter, the IN enzyme catalyzes its initial 
activity, 3’ processing, whereby each vDNA 3’ end is cleaved adjacent to the conserved 
dinucleotide sequence CpA. This marks the transition from the RTC to the PIC, wherein 
IN catalyzes its second catalytic function, DNA strand transfer [168,169]. Concomitantly, 
the complexes undergo morphological transitions, such as the dissolution of the viral CA 
core, as they traffic from the cellular periphery to desired regions of host DNA within the 
nucleus [44,49,56,128]. Well-studied but still-unresolved aspects of these steps are the 
mechanisms by which retroviruses bypass the nuclear envelope, which physically 
separates the nuclear and cytoplasmic compartments of the cell (reviewed in [170]). 
Although certain viruses, such as the gammaretrovirus MLV, are believed to require the 
dissolution of the nuclear membrane during mitosis [21], lentiviruses such as HIV-1 are 
able to infect nondividing cells and thus are believed to traverse the nuclear membrane by 
passing through the NPC [115,171]. As the HIV-1 PIC has been estimated to have a 
stokes radius of 28 nm [79] and thus grossly exceeds the ~9-nm diffusion limit [172] of 
the NPC, lentiviruses theoretically possess at least one mechanism to hijack the nuclear 
transport machinery and actively transport their PICs through the pore. 
A number of HIV-1 PIC components, including MA, Vpr, IN, and the central 
DNA flap formed during reverse transcription, have been proposed to function during 
26 
nuclear import, although significant roles for any of these components during this step 
have not been well corroborated. This may, at least in part, be reflective of redundant PIC 
nuclear import mechanisms, although viruses with these elements mutated in 
combination did not exhibit obvious cell cycle-dependent infectivity or nuclear import 
defects [106,173]. In contrast, CA can determine the ability of HIV-1 to infect 
nondividing cells, suggesting that viral core uncoating is a rate-limiting step of lentiviral 
PIC nuclear import [57,174]. 
Numerous studies also have examined the requirements for specific cellular 
proteins during lentiviral/HIV-1 PIC nuclear import, including nuclear transport proteins 
NUP98 [175], importin 7 [176], KPN α2 Rch1 [76], and importin α3 [91]. A series of 
three genome-wide siRNA screens [28-30] highlighted nuclear transport proteins whose 
depletion strongly inhibited the early steps of HIV-1 infection. This included TNPO3 or 
transportin-SR2, a member of the KPN β superfamily responsible for transporting 
splicing factors with SR motifs into the nucleus. The depletion of TNPO3 resulted in a 
sizable HIV-1 nuclear import defect [70] while infection by MLV or the lentivirus feline 
immunodeficiency virus (FIV) remained largely unaffected [96,177,178], suggesting 
TNPO3 dependence to be specific to, although perhaps not obligatorily required by, 
lentiviruses. The mechanism by which HIV-1 physically hijacks TNPO3 remains 
unsolved; even though TNPO3 can bind HIV-1 IN [70], comparable levels of binding to 
MLV and FIV INs were observed [96,178], and analyses of HIV-1 proteins relevant 
during the infection of TNPO3 knockdown cells implicated the CA protein as the genetic 
determinant of TNPO3 dependency [96]. 
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In addition to TNPO3, two major constituent proteins of the NPC, nucleoporins 
NUP358/RanBP2 and NUP153, were identified in two of the siRNA screens [28,29]. 
NUP358 composes the large cytoplasmic filaments emanating from eukaryotic NPCs 
[144], the knockdown of which was recently confirmed to result in a defect of HIV-1 
nuclear entry during infection [179]. NUP153 is localized within the nucleus, linking 
central NPC scaffolding subcomplexes with their corresponding nuclear basket 
substructure, as well as anchoring individual NPCs with the nuclear lamina [180]. 
Additionally, NUP153 dynamically shuttles between NPC-localized and nucleoplasmic 
populations [181]. Although NUP153 knockdown also was interpreted to result in a 
defect in HIV-1 nuclear import, the lack of clear correlation between an approximately 
85% reduction in acute infection and 20% reduction in 2-long terminal repeat 2- LTR-
containing DNA circle levels, a marker for PIC entry into the nucleus [29], suggested to 
us that other factors were at play. NUP153 has been reported to bind HIV-1 IN and Vpr 
[98,182], suggesting potential mechanistic clues for the role of this host factor during 
HIV-1 infection. To investigate how NUP153 facilitates HIV-1 infection, we analyzed 
viral determinants that render HIV-1 sensitive to NUP153 depletion and additionally 
performed qPCR analyses of the viral DNA species formed during the infection of 
NUP153 knockdown cells. 
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Results 
 
Depletion of NUP153 expression inhibits HIV-1 infection. 
RNAi was used to knock down NUP153 expression and analyze the role of this 
host factor during HIV-1 infection. HeLa cells were transfected with one of two 
previously characterized NUP153-specific siRNAs [183,184] or a nontargeting siControl 
mismatch to siNUP153#1, and protein expression levels were measured 48 h later. 
Western blotting of whole-cell lysates showed NUP153 expression to be depleted greater 
than 8-fold by either siRNA (Figure 2-1A). NUP153 knockdown cells infected with 
HIV-1 or MLV revealed that siNUP153#1 and siNUP153#2 significantly reduced HIV-1 
infectivity to 3.2 and 3.4% of siControl-treated cells, respectively (Figure 2-1B). MLV 
was less or not significantly inhibited in parallel infections. Because cells transfected 
with siNUP153#2 showed evidence of cytotoxicity (data not shown), siNUP153#1 was 
used for the remainder of the study. 
To further address the specificity of NUP153 knockdown on HIV-1 infection, 
protein levels in depleted cells were restored via expression of an exogenously introduced 
siRNA-insensitive cDNA. siRNA-transfected HEK293T cells were retransfected with the 
inert pUC19 plasmid, an empty expression vector encoding an internal ribosome entry 
site (IRES)-controlled dsRed-Express fluorescent protein, or an engineered vector 
encoding NUP153 5’ of the IRES element. Western blot analysis of cells lysed at the time 
of infection showed more robust exogenous NUP153 expression than the endogenous 
protein in both knockdown and control cells (Figure 2-1C). As gross overexpression of 
NUP153 has been shown to distort the nuclear envelope [185], virus-infected green  
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Figure 2-1. NUP153 expression and HIV-1 infection. (A) Twofold dilutions of a whole-cell 
extract from control cells (lanes 1 to 4) compared to extracts from NUP153-depleted cells (lanes 
5 and 6). NUP62 cross-reacted with the utilized anti-NUP153 antibody. (B) Percent infectivity of 
GFP reporter viruses in HeLa cells transfected with siNUP153#1 (dark gray) or siNUP153#2 
(light gray) compared to control cells. Results are averages from three experiments, each 
performed in triplicate; error bars denote 95% confidence intervals. (C) HEK293T cells 
transfected with siControl or siNUP153#1 were retransfected with either control DNA (pUC19), 
empty IRES-dsRed-Express vector, or the vector expressing siRNA-resistant NUP153 protein. 
(D) Cells in panel C were gated for dim dsRed-Express expression, and the infectivities of GFP 
reporter viruses were normalized to those of cells transfected with the empty vector. Solid and 
hatched bars, cells transfected with siControl and siNUP153#1, respectively; dark and light gray 
bars, cells transfected with empty and NUP153 expression vectors, respectively. The results are 
averages from four experiments performed in duplicate, with error bars denoting 95% confidence 
intervals. 
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fluorescent protein (GFP)-positive cells were quantitated within cell populations gated for 
the dim fluorescence of the dsRed-Express protein. HIV-1 infection of NUP153 
knockdown HEK293T cells was significantly inhibited compared to the infection of 
control cells, while exogenous NUP153 expression restored infection to levels similar to 
those of controls (Figure 2-1D). Although MLV in this experiment was partially affected 
by NUP153 knockdown, this effect was inert to NUP153 reexpression. 
 
Differential retroviral dependencies on cellular NUP153. 
We investigated whether NUP153 dependency was specific or common to 
lentiviruses by testing the infectivities of a panel of retroviral reporter constructs. To 
determine whether the stark infectivity defect observed with HIV-1 extended to other 
primate lentiviruses, GFP reporter viruses for HIV-2ROD, SIVMAC, SIVAGMTan, and 
SIVAGMSab were analyzed. NUP153 depletion significantly inhibited infection by each of 
these viruses, with values ranging from 3.3% for SIVAGMTan to 10.6% for SIVMAC, while 
infection by MLV was slightly enhanced under these conditions (Figure 2-2A). In 
contrast, similar experiments showed more-divergent retroviruses to be less sensitive to 
NUP153 depletion (Figure 2-2B). NUP153 knockdown significantly inhibited equine 
infectious anemia virus (EIAV) infection, to 33.4% of the level for the control. The 
alpharetrovirus Rous sarcoma virus (RSV) and betaretrovirus Mason-Pfizer Monkey 
Virus (MPMV) also were significantly affected but to even lesser extents, at 53.7 and 
38.7% of the control level, respectively (Figure 2-2B). Consistently with results of Lee et 
al. [177], infection by FIV was largely unaffected by NUP153 knockdown. 
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Figure 2-2. Retroviral susceptibilities to NUP153 knockdown. HeLa cells transfected with 
siNUP153#1 or siControl were infected with GFP reporter viruses specific to primate lentiviruses 
(A) or different types of retroviruses (B). Results are averages from at least three experiments 
performed in triplicate, with error bars denoting 95% confidence intervals. 
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Neither Vpr nor the central DNA flap play significant roles in NUP153 dependency 
during HIV-1 infection. 
Viral elements implicated in HIV-1 nuclear import were analyzed to determine 
which ones might contribute to NUP153 dependency. Neither the central DNA flap nor 
Vpr are essential for HIV-1 infectivity, so mutations that completely abrogated function 
were analyzed here [114,186]. Reporter viruses with either or both elements mutated 
were applied to NUP153 or control knockdown cells at two levels of input: 5 x 10
6
 or 5 x 
10
4
 RT-counts per minute (RTcpm). Similarly to previous observations, single and 
double mutant viral infectivities were comparable to that of the WT [106,114,186] 
(Figure 2-3A, dark gray bars). To determine whether sensitivity to NUP153 depletion 
was altered by these mutations, the infectivities of each mutant virus in knockdown cells 
were normalized to their corresponding control sample and regraphed (Figure 2-3B). 
Infections performed with either quantity of viral inocula were significantly decreased 
when NUP153 was knocked down, although as a group infections performed with less 
virus showed a slight, but not significant, increase in sensitivity to the knockdown. 
Although Vpr mutant viruses showed slight differences in sensitivity to the knockdown 
with both quantities of inocula, none of these values reached statistical significance. 
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Figure 2-3. NUP153 dependency during HIV-1 infection is independent of Vpr and the 
central DNA flap. (A) Viral infectivities were normalized to the level obtained with 5 × 10
6
 
RTcpm of WT virus (set to 100%). Dark gray, siControl; light gray, siNUP153#1. (B) Regraph of 
panel A results, with infectivities in knockdown cells expressed as percentages of control cells, 
which were set at 100%. Solid dark gray, WT virus; light gray, DNA flap mutant; hatched bars, 
Vpr mutant viruses. Results are averages from four experiments performed in duplicate, with 
error bars denoting 95% confidence intervals. RLU, relative light units. 
34 
Replacement of HIV-1 IN or CA with MLV counterparts influences NUP153 
dependency, while MA does not. 
Essential roles of MA, IN, and CA proteins during the early and/or late steps of 
HIV-1 replication precluded the use of deletion constructs in infectivity assays. Because 
NUP153 depletion resulted in dramatically different levels of MLV and HIV-1 infection 
[29] (Figure 2-1B), we instead tested a set of HIV-1-based chimera viruses containing 
differing amounts of MLV Gag and/or Pol proteins [116,173] (Figure 2-4A). Chimera 
viral names indicate the swapped MLV protein(s). For example, mMAp12 carries MLV 
MA and p12, whereas mMAp12CA additionally harbors MLV CA. 
Upon NUP153 depletion, the infectivity of the parental HIV-1LAI isolate was 
significantly decreased to 2.1% of that of the control, while MLV remained unaffected at 
112.1% (Figure 2-4B). The infectivity of mMAp12 was indistinguishable from that of 
HIV-1LAI, while the addition of MLV CA reduced dependency on NUP153 about 10-fold, 
to 22.7% of that of the control. The separate replacement of the IN protein in mIN also 
yielded a significant, approximately 4-fold difference from HIV-1LAI to 9.1% of that of 
the control, although this sample exhibited greater experimental variability. The 
combination virus containing MLV MA, p12, CA, and IN was not inhibited by NUP153 
depletion, exhibiting 149.6% infectivity compared to that of the control. 
35 
 
 
 
 
 
Figure 2-4. NUP153 dependencies of MLV / HIV-1 chimera viruses. (A) Illustration of 
constructs tested (not to scale), with major HIV-1 Gag and Pol proteins indicated in gray (NC, 
nucleocapsid; PR, protease) and MLV proteins in white. (B) Control or knockdown cells were 
infected with HIV-1LAI, MLV, or HIV-1-derived MLV chimera viruses shown in panel A. Results 
are averages from three experiments performed in triplicate, with error bars denoting 95% 
confidence intervals. 
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Alteration of HIV-1 sensitivity to NUP153 depletion by CA missense mutations or 
cyclosporine treatment. 
The preceding experiment revealed CA as a dominant determinant of NUP153 
dependency, so we next surveyed a panel of previously characterized CA missense 
mutant viruses for NUP153 dependency during infection. Mutants of the CypA binding 
loop, encompassing HIV-1 residues His83 to Arg99, included G89V and P90A, which 
exhibit greatly diminished CypA binding [187], and A92E and G94D, whose infectivities 
are cell type specific [188,189]. Non-CypA loop mutants E45A and Q63A/Q67A, which 
exhibit altered core stability both in vitro and ex vivo [57,119,120,190], experience 
greatly decreased infectivities across cell types. A relatively large viral inoculum, 4 x 10
6
 
RTcpm, therefore was utilized to provide robust signals across the mutant virus set. 
Consistently with previous reports, the infectivities of E45A and Q63A/Q67A 
were severely compromised, while G89V, A92E, and G94D yielded moderate defects 
and the N74D and P90A mutants infected HeLa cells at levels comparable to that of the 
WT (Figure 2-5A, dark gray bars). Comparison of infectivities in knockdown and control 
cells confirmed N74D to be insensitive to NUP153 depletion [177] (Figure 2-5A and 2-
5B, light gray bars). E45A appeared moderately less sensitive to knockdown than the 
WT, while the Q63A/Q67A mutant was not distinguishable from the WT. A92E and 
G94D were at least as, if not more, sensitive to NUP153 depletion as the WT, while the 
CypA binding mutants G89V and P90A exhibited contrasting sensitivities: G89V was 
sensitive while P90A was resistant (Figure 2-5A and 2-5B, light gray bars). The P90A  
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Figure 2-5. WT and CA mutant viral infectivities and cyclosporine dependences in control 
and NUP153 knockdown cells. (A) Control (dark gray) or NUP153 knockdown (light gray) cells 
were left untreated (solid bars) or were treated with 5 µM cyclosporine (hatched bars) at the time 
of infection. All samples were normalized to the infectivity of WT virus in untreated control cells, 
which was set at 100%. The results are averages from three experiments, each performed in 
duplicate, with error bars denoting 95% confidence intervals. (B) Regraph of panel A results, 
with infectivities in knockdown cells expressed as percentages of the infectivity of control cells; 
hatched bars denote infections in the presence of CsA. The results are averages from six 
experiments performed in duplicate, with error bars denoting 95% confidence intervals. (C) 
Infectivities in NUP153 knockdown cells compared to that of control cells, with hatched bars 
denoting cells in which CypA was simultaneously depleted. Results are averages from two 
experiments performed in duplicate, with error bars denoting 95% confidence intervals. 
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phenotype appeared to be cell type specific, as partial sensitivity to NUP153 knockdown 
was observed in HEK293T and GHOST-CXCR4 cells (data not shown). 
 As the interaction of CA with CypA can govern HIV-1 uncoating [191], WT and 
CA mutant viral dependencies were evaluated in the presence of cyclosporine to disrupt 
this protein-protein interaction. As previously observed in HeLa cells [188,192], the WT 
was relatively unaffected by cyclosporine treatment, while E45A, Q63A/Q67A, A92E, 
and G94D witnessed approximately 5- to 10-fold increases in infectivity (Figure 2-5A, 
compare dark gray hatched and solid bars). Interestingly, cyclosporine treatment rendered 
the WT, A92E, and G94D viruses fully insensitive to NUP153 depletion (Figure 2-5A, 
dark gray hatched bars, and 2-5B, hatched bars). This effect was not observed with all 
NUP153-sensitive CA mutants, as the G89V mutant remained largely dependent on the 
host factor in the presence of the drug. Similar results were observed with CypA 
knockdown in place of cyclosporine treatment: CypA knockdown resulted in 
approximately 5- to 20-fold increases in the infectivities of E45A, Q63A/Q67A, A92E, 
and G94D mutant viruses (data not shown), and WT, A92E, and G94D viruses were 
rendered significantly less sensitive to NUP153 depletion when CypA was knocked down 
simultaneously (Figure 2-5C, compare hatched to solid bars). 
 
Interdependent requirement for NUP153 and TNPO3 during HIV-1 infection. 
Primate lentiviruses revealed strong dependencies on NUP153 and TNPO3, while 
MLV, FIV, and the N74D HIV-1 CA mutant virus were largely unaffected by either 
knockdown [96,177] (Figure 2-2). We therefore tested if these proteins would reveal 
evidence for interdependence during HIV-1 infection. Because Thys et al. [178] recently  
39 
 
 
 
 
 
 
 
 
 
Figure 2-6. Interdependence of NUP153 and TNPO3 during HIV-1 infection. (A) Whole-cell 
extracts of control, NUP153-depleted, TNPO3-depleted, and combinatorially depleted cells were 
blotted with the indicated primary antibodies. (B) Control (dark gray) or NUP153 knockdown 
(light gray) cells simultaneously depleted for TNPO3 (hatched bars) were infected with 2 × 10
6
 or 
2 × 10
7
 RTcpm of vesicular stomatitis virus (VSV)-G or HIV-1 envelope pseudotyped viruses, 
respectively, yielding numbers of RLU in control cells that were within 1 log of each other (not 
shown). All samples were normalized to the infectivity of the WT virus in control cells, which 
was set at 100%. White bars show the multiplicative product of infectivity defects exhibited upon 
individual protein knockdowns, representing the theoretical maximum expected assuming 
independent function. Results are averages from three experiments, each performed in duplicate, 
with error bars denoting 95% confidence intervals. 
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showed that the route of N74D entry influenced the requirement for TNPO3, experiments 
were conducted in CD4-positive GHOST-CXCR4 cells to enable comparisons of VSV-G 
and HIV-1 envelope pseudotyped particles. NUP153 and TNPO3 were knocked down 
either individually or in combination (Figure 2-6A). WT viruses carrying either envelope 
exhibited 3- to 5-fold decreases in infectivity when NUP153 (Figure 2-6B, light gray 
bars) or TNPO3 (dark gray hatched bars) was knocked down, while N74D was largely, if 
not completely, insensitive. Interestingly, a 40-fold decrease in infection by VSV-G-
pseudotyped WT virus was observed when both proteins were knocked down (Figure 2-
6B, light gray hatched bar), far greater than the ~ 14-fold defect expected based on the 
product of individual knockdowns (Figure 2-6B, white bar). The N74D mutant showed 
no such effect, with the dual knockdown inhibiting this virus no more than the slight 
decrease observed with NUP153 knockdown alone. The results with the HIV-1 envelope 
pseudotypes were similar, although slightly exaggerated: WT virus exhibited an 
approximately 75-fold infection defect when both factors were knocked down, while the 
N74D mutant exhibited a much smaller, though noticeable, 3-fold decrease in infectivity. 
 
NUP153 depletion inhibits expression from an integration-defective reporter virus. 
HIV-1 reporter viruses harboring mutations of IN active-site residues are unable 
to catalyze vDNA integration but still can yield a reproducible level of reporter gene 
expression. N/N active-site mutant viruses carrying either WT or N74D CA therefore 
were produced to determine if the inhibitory effects of NUP153 depletion were conferred 
in the absence of integration. Infection with N/N mutant viruses yielded ~ 2 to 3% 
reporter expression compared to that of the WT IN viruses, and as expected, these gene  
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Figure 2-7. NUP153 dependencies of WT and IN active-site mutant viruses. (A) Relative 
differences in reporter expression of 5 × 10
6
 RTcpm WT and N/N IN mutant, along with WT 
sequence or the CA N74D mutation, in the absence (dark gray) or presence (light gray) of 10 µM 
raltegravir. (B) Relative infectivities of WT and N/N mutant viruses in control (dark gray) or 
NUP153 knockdown cells (light gray), with WT infectivity (5 × 10
6
 RTcpm) set to 100%. 
Viruses harbored either WT (solid bars) or N74D (hatched bars) CA. (C) Regraph of panel B 
results, with infectivities in knockdown cells expressed as percentages of respective control cells; 
solid, hatched, and boldface hatched bars denote infections with 5 × 10
6
, 5 × 10
5
, and 5 × 10
4
 
RTcpm of WT IN virus, respectively, while light gray bars denote infection with N/N virus. 
Results are averages from five experiments performed in triplicate, with error bars denoting 95% 
confidence intervals. 
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expression levels were completely refractory to the addition of 10 µM strand transfer 
inhibitor raltegravir, a dose ~ 100-fold in excess of that required to inhibit 95% of WT 
viral infection [193] (Figure 2-7A). Control and NUP153 knockdown cells next were 
challenged with N/N viruses alongside 10-fold dilutions of WT IN viruses to establish a 
comparable level of endpoint reporter expression (Figure 2-7B). The N/N virus 
harboring WT CA was significantly inhibited by NUP153 depletion to a level 
indistinguishable from that of its integration-competent counterpart at all viral inocula 
tested (Figure 2-7C). Additionally, similarly to the effects of the N74D change on 
integrating virus, the N74D CA mutation rendered the N/N virus insensitive to NUP153 
depletion. 
 
NUP153 depletion results in decreased 2-LTR circles and integrated proviruses. 
Although NUP153 depletion was previously concluded to result in an HIV-1 PIC 
nuclear import defect, this interpretation was based on an approximately 20% reduction 
in 2-LTR circle levels at 24 hpi alongside an 8-fold infectivity defect [29]. To more 
comprehensively address the block to HIV-1 infection upon NUP153 depletion, LRT, 2-
LTR circle, and integrated proviral DNA levels were measured at multiple time points by 
qPCR following infection with either WT or N/N mutant virus. As expected [194], cells 
infected with N/N virus supported a level of LRT products similar to that of WT-infected 
cells at 8 hpi, with a corresponding ~ 9.6 fold increase in 2-LTR circle levels at 24 hpi 
(data not shown). WT and N/N mutant viral reverse transcription were insensitive to the 
amount of cellular NUP153, as peak levels at 8 hpi were similar in control and 
knockdown cells (Figure 2-8A and 2-8D). NUP153 depletion resulted in an  
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Figure 2-8. HIV-1 DNA species formed during acute infection of NUP153 knockdown cells. 
Viral DNAs were amplified from cells following infection with WT (A, B, and C) or N/N mutant 
(D and E) virus, with values from NUP153 knockdown cells (gray dashed line) normalized to 
peak LRT (8 hpi) (A and D), 2-LTR circle (24 hpi) (B and E), and integration (52 hpi) (C) 
values. (F) Levels of WT and N/N mutant virus infectivities upon NUP153 depletion, expressed 
as percent siControl-transfected cells (set at 100%). Results are averages from three experiments, 
with error bars denoting 95% confidence intervals. 
44 
approximately 4.7-fold decrease in N/N virus 2-LTR circle formation at 24 hpi, which 
leveled off somewhat, to 3.2-fold, by 52 hpi (Figure 2-8E). In contrast, NUP153-
depleted cells infected with WT virus supported 2.1- and 2.3-fold lower 2-LTR circle 
levels than siControl transfected cells at 24 and 52 hpi, respectively (Figure 2-8B). WT 
viral integration was blocked more significantly than 2-LTR circles in NUP153 
knockdown cells, about 5- and 7.2-fold lower than the levels of integrated proviruses in 
control cells at 24 and 52 hpi, respectively (Figure 2-8C). Comparison of luciferase 
activities at 52 hpi yielded approximately 9.3- and 10.7-fold reductions in WT and N/N 
mutant viral infectivities, respectively, upon NUP153 knockdown (Figure 2-8F). 
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Discussion 
 
NUP153 is likely required for HIV-1 nuclear entry. 
NUP153 expression has been shown to be required for HIV-1 infection [28,29], 
but its role(s) in this process has yet to be well characterized. Here, we show that 
NUP153 is required for efficient infection by primate lentiviruses and may play a role in 
infection by other retroviral genera (Figure 2-2). Our results with integration-defective 
N/N virus revealed NUP153 to be equally required for expression from integrated and 
unintegrated vDNA templates, implicating a step common to both processes. Our 
investigations tracking viral DNA accumulation in NUP153-depleted cells showed both 
WT and N/N IN mutant viral LRT levels similar to those of control cells, suggesting that 
NUP153 expression is not necessary for reverse transcription. In contrast, knockdown 
cells infected with the N/N mutant supported formation of about 5-fold fewer 2-LTR 
circles than NUP153-expressing cells (Figure 2-8). The nonhomologous end-joining 
machinery required for 2-LTR circle formation is expected to reside in the nucleus 
[61,62,195], which suggests that NUP153 is involved at a step(s) following reverse 
transcription which could precede or coincide with nuclear entry or a subsequent process 
that facilitates the formation and/or retention of 2-LTR circles. Because NUP153 is an 
NPC component, it seems most likely that the defect is at nuclear entry. Accordingly, 
knockdown cells infected with WT virus exhibited decreased levels of 2-LTR circles as 
well, albeit to a lesser extent than the N/N mutant. This discrepancy may be due to an 
overlying integration defect, which would be expected to contribute to the accumulation 
of vDNAs susceptible to circularization. 
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CA mutant viruses and cyclosporine treatment indicate a role for core uncoating in 
NUP153 dependency during HIV-1 infection. 
Although the infection defect is likely at a nuclear step, the major functional 
determinant of NUP153 dependency identified thus far appears to be the CA protein 
[177] (Figure 2-4 to 2-6). It is possible that CA molecules associated with the PIC 
directly participate in steps at the NPC or within the nucleus, but because numerous point 
mutations across different faces of the HIV-1 CA monomer can dramatically alter 
NUP153 dependence, it is more likely that the dominant effects of CA are reflective of 
qualities conferred by a multimerized CA core. These results suggest that NUP153 
dependency is an effect dictated by the manner in which the CA core uncoats in the 
cytoplasm or potentially at the nuclear pore itself [80]. Consistent with this interpretation, 
we found that the perturbation of cyclophilin binding, either by cyclosporine treatment or 
CypA knockdown, dictated the sensitivity of the WT and cyclosporine-dependent 
mutants A92E and G94D to NUP153 depletion (Figure 2-5). Thus, it appears as though 
the amount of CypA bound to the HIV-1 core is able to dictate whether the PIC 
undergoes downstream processes requiring NUP153, perhaps by altering the dynamics of 
uncoating [191]. 
Notably, this level of regulation by CypA does not appear to be a global requisite 
for infection, as SIVMAC is highly sensitive to NUP153 knockdown in spite of its reported 
inability to bind CypA [196]. The route of cell entry taken by the N74D CA mutant, 
which has been documented to alter the requirement for TNPO3 during infection [178], 
may influence NUP153 dependency as well. Although the HIV-1-mediated entry of 
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N74D failed to reveal a requirement for NUP153 or TNPO3 in our hands, we did note a 
modest 3-fold effect upon the depletion of both proteins (Figure 2-6). Notably, there is 
precedence for a requirement of NUP153 and NUP153-like proteins during infection with 
other viruses and retrotransposons at a stage that interfaces capsid oligomerization with 
nuclear import. The Saccharomyces pombe ortholog Nup124p is important for the 
nuclear accumulation of the Tf1 retrotransposon [197,198]. Interestingly, residues 
adjacent to an N-terminal nuclear localization signal located in Tf1 Gag dictated whether 
Nup124p was necessary for Gag nuclear import, and this appeared to correlate with the 
ability of Gag to multimerize [199]. More recently, NUP153 was found to play a key role 
during hepatitis B virus nuclear import by signaling mature capsid proteins to dissociate 
within the NPC basket [200]. Interestingly, both Tf1 Gag and hepatitis B virus capsid 
have been demonstrated to directly bind their respective NUP153 orthologs. It therefore 
would be instructive to know if human NUP153 binds HIV-1 CA in an oligomerization-
dependent manner. 
 
A potential role for IN in NUP153 dependency. 
Aside from the dominant effects conferred by CA, our functional studies of viral 
elements provide context to understand potential physical interactions relevant to 
NUP153 function during infection. Although NUP153 has been found to bind HIV-1 Vpr 
[182], viruses lacking virion-incorporated Vpr were not significantly altered in their 
NUP153 dependence compared to that of the WT virus, suggesting that this interaction is 
not relevant up to and including the nuclear import, integration, and early gene 
expression stages of infection (Figure 2-3). NUP153 also has been found to bind HIV-1 
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IN [98], and our results with MLV/HIV-1 chimera viruses support a role for HIV-1 IN 
during the infection of NUP153 knockdown cells (Figure 2-4). Additionally, the IN 
protein of FIV previously was found not to bind NUP153 [98], which appears to correlate 
with the insensitivity of this virus to NUP153 depletion (Figure 2-2B). As yet, the 
requirement for IN appears auxiliary to CA: despite carrying WT IN, HIV-1 CA mutants 
N74D and P90A were largely insensitive to NUP153 knockdown (Figure 2-5 and 2-6), 
while comparison between chimeras containing MLV IN or CA showed the replacement 
of CA to decrease the sensitivity of the virus to knockdown more than IN replacement 
(Figure 2-4). 
 
Pleiotropic effects of NUP153 depletion. 
It is currently unknown whether the effect of NUP153 knockdown on primate 
lentiviral infection is reliant on the cellular roles of NUP153 during nuclear transport or 
on other collateral pleiotropic effects caused by the depletion of this multifunctional 
protein. NUP153 is believed to be a major point of NPC interaction with translocating 
KPNs, including those for nuclear import via importin α/β and transportin, protein export 
via Crm1, and mRNA export via NXF1 (reviewed in [201]). Furthermore, NUP153 
depletion has been shown to prevent the NPC from incorporating nucleoporins Tpr and 
NUP50 [159,184], and it also has been shown to perturb NUP62, NUP88, and NUP214 
localization in certain contexts [184,202]. Thus, even if the disruption of a putative 
specific HIV-1 PIC-NUP153 interaction(s) is not the root cause of the infectivity defect, 
it may be due to the mislocalization of a subsequently required, potentially unidentified 
host factor. Furthermore, NUP153 can exert effects indirectly of nuclear transport, as its 
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depletion has been shown to disrupt the cytoskeleton [203], likely through the 
perturbation of the nuclear lamina, and it also has been found to delay cellular 
progression through mitosis [184,204]. Lastly, NUP153 is important during transcription 
and even has been found to be associated with large regions of transcriptionally active 
open chromosomes within the Drosophila genome [205]. Regardless, although NUP153 
depletion is known to disrupt many processes within the cell, its overall relevance to 
HIV-1 infection must be relatively specific, as single point mutations in CA can render 
the virus completely unaffected (Figure 2-5). 
It will be interesting to continue to determine the role of NUP153 in relation to 
other host factors implicated in HIV-1 nuclear transport, especially TNPO3 and NUP358. 
Numerous similarities have been observed upon the knockdown of individual 
components: HIV-1 exhibits a nuclear entry defect [29,70,179] (Figure 2-8), while MLV, 
FIV, and the N74D CA mutant virus are seemingly unaffected [28,29,70,96,177,178] 
(Figures 2-2, 2-5, and 2-6). Here, we determined that the simultaneous depletion of 
NUP153 and TNPO3 significantly enhanced the block to HIV-1 infection, suggesting 
interrelated functions. Perhaps these proteins represent multiple components of a 
concerted mechanism streamlining the early steps of HIV-1 infection, allowing for both 
optimal quantity and quality of proviral insertion into the host genome. 
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Materials and Methods 
 
Plasmid constructs. 
Infection assays utilized single-round viruses carrying either GFP or luciferase 
reporter genes. GFP-based constructs included: EIAV [206,207], HIV-1 [208], RSV 
[209] (Addgene plasmid 13878 obtained from Constance Cepko via Addgene), FIV 
[210,211], MLV [212,213], MPMV [214], HIV-2 strain ROD (HIV-2ROD), and simian 
immunodeficiency virus from Macaca mulatta (SIVMAC), Chlorocebus sabaeus 
(SIVAGMSab), and Chlorocebus tantalus (SIVAGMTan) [215]. Luciferase-based viruses 
included MLV/HIV-1LAI chimeras [116,173] and HIV-1NL4-3-derived D64N/D116N 
(N/N) IN active site and Vpr and/or DNA flap mutants of pNLX.Luc [102,216]. VSV-G 
and HIV-1NL4-3 glycoprotein expression vectors were as described [102,216]. 
HIV-1 CA mutations were generated through site-directed mutagenesis of the 
HIV-1NL4-3-based pHP-dI-N/A packaging plasmid [217] (AIDS Research and Reference 
Reagent Program [ARRRP]), which was co-transfected in conjunction with either pHI-
vec2.GFP [218] or pHI-Luc [219] transfer vectors. Sequencing was used to verify PCR-
mutated DNAs. NUP153 expression vector pIRES-dsRedExpress-NUP153 was created 
by digesting pCMV-Sport6-NUP153 (Open Biosystems) with Sal I and Bgl II, and 
ligating the resulting NUP153-coding fragment with Sal I/BamH I-digested pIRES-
dsRedExpress (Clontech Laboratories). 
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Cells and siRNA transfections. 
HEK293T and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented to contain 10% fetal bovine serum, 100 IU/ml penicillin, and 100 µg/ml 
streptomycin, while GHOST cells expressing CD4 and the CXCR4 co-receptor (GHOST-
CXCR4) [220] (ARRRP) were additionally cultured with 500 µg/ml G418, 100 µg/ml 
hygromycin, and 1 µg/ml puromycin.. Approximately 75,000 HEK293T or 25,000 HeLa 
or GHOST-CXCR4 cells seeded per well of a 24-well plate were transfected the next day 
with a final concentration of 40 nM siNUP153#1 (GGACTTGTTAGATCTAGTT) [184], 
10 nM siNUP153#2 (AGTGTTCAGTATGCTGTGTTTCT) [183], or 40 nM of 
mismatch control of siRNA #1, referred to as siControl (GGTCTTATTGGAGCTAATT; 
underlines indicate base mismatches with siNUP153#1)) (Dharmacon) using RNAiMax 
(Invitrogen) according to the manufacturers instructions. Simultaneous NUP153 and 
cyclophilin A (CypA) knockdown was performed by transfection with a final 
concentration of 20 nM siNUP153#1, 20 nM CypA siRNA 
(AAGGGTTCCTGCTTTCACAGA) [221], or the corresponding amount of siControl for 
a total siRNA concentration of 40 nM. Simultaneous NUP153 and TNPO3 knockdown 
was performed similarly, using siTNPO3 (CGACATTGCAGCTCGTGTA) [96]. Media 
was exchanged the following day. NUP153 re-expression was performed by CaPO4 
transfection of 1 µg DNA immediately after siRNA transfection. 
 
Virus production. 
Vector particles were generated by transfecting HEK293T cells in 10-cm plates 
with 10 µg total of various ratios of the aforementioned virus production plasmids using 
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either CaPO4 or Fugene 6 (Roche Molecular Biochemicals). The cells were washed 16 h 
after transfection, and supernatants collected 12 to 60 h thereafter were clarified at 300 x 
g, filtered through 0.45µm filters (Nalgene), and either allotted and frozen or 
concentrated by ultracentrifugation using an SW28 rotor at 53,000 x g for 2 h at 4°C 
before freezing. Concentrations of Vpr, DNA flap, and CA mutant viral stocks were 
determined alongside concomitantly produced WT viruses using an exogenous 
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P-based 
RT assay [222]. 
 
Infectivity assays. 
Control and siRNA knockdown cells seeded onto 48-well plates were infected 
overnight with various reporter viruses 48 h post-siRNA transfection. Percentages of 
GFP-positive cells were determined 36 h post infection (hpi) using a FACSCanto flow 
cytometer (BD) equipped with FACSDIVA software. GFP reporter experiments were 
performed with virus inoculates adjusted to yield < 40% GFP-positive cells in control 
samples. Cells were infected with equal RTcpm of WT or mutant HIV-1 luciferase 
reporter viruses, while MLV chimera viruses were adjusted such that all infections were 
approximately within 2 log RLU/µg/sec of control cells. Where applicable, cyclosporin A 
(CsA) (Sigma) was added at the time of infection to the final concentration of 5 µM. 
Cells infected with luciferase reporter viruses were lysed 48 hpi unless otherwise noted, 
and resulting levels of luciferase activity were normalized to the corresponding levels of 
total protein in cell extracts as described previously [96]. 
 Normalized infectivity data were log transformed, and statistical analyses were 
performed by paired two-tailed Student’s t-test. Mean infectivity values were then back 
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transformed for graphical representation, with error bars denoting 95% confidence 
intervals. 
 
Western blot analysis. 
At the time of infection, siRNA treated cells were lysed with 
radioimmunoprecipitation assay buffer (20 mM HEPES [pH 7.5], 150 mM NaCl, 1% NP-
40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 0.5 M EDTA, Complete 
protease inhibitor [Roche Molecular Biochemicals]). Following determination of protein 
concentration by Bradford assay, 60 µg or two-fold dilutions of each lysate were 
fractionated through 9% Tris-glycine gels, and proteins were transferred onto a 
polyvinylidene fluoride membrane. NUP153 and NUP62 were detected using a 1:2,500 
dilution of mouse mAb414 antibody (Abcam Inc.), while TNPO3 was detected using a 
1:150 dilution of mouse anti-TNPO3 antibody ab54353 (Abcam Inc.). A 1:5,000 dilution 
of rabbit anti-mouse horseradish peroxidase-conjugated served as secondary antibody 
(Dako North America Inc.), and a 1:5,000 dilution of mouse anti-α-tubulin antibody 
(Abcam Inc.) was used for loading control. Blots were developed using the ECL Plus 
detection reagent (GE Healthcare). 
 
QPCR. 
siNUP153#1 or siControl-transfected cells (500,000) were infected with ~2x10
7
 
RTcpm of DNase-treated WT or N/N mutant virus, with parallel infections conducted in 
the presence 100 µM azidothymidine (AZT) to define residual plasmid DNA levels 
potentially carried over from transfection. Two hours later, infected cells washed with 
54 
phosphate-buffered saline were re-plated into individual 24-wells. Cells were collected at 
various time points, and DNA was extracted with a QIAamp DNA Mini Kit as 
recommended by the manufacturer (Qiagen). Each sample was analyzed in triplicate by 
qPCR to determine levels of HIV-1 LRT-products, 2-LTR containing circles, and 
integrated proviruses via nested Alu-PCR essentially as described previously [51,223]. 
LRT and 2-LTR circle values were normalized to qPCR values for β-globin DNA 
performed in parallel, while all input DNAs for first-round Alu-PCRs were adjusted for 
equal β-globin amplification. Values obtained from corresponding AZT-treated samples, 
which averaged 2.6% of peak LRT and 2.5% of peak 2-LTR circles, were subtracted 
from non drug-treated values. 
Plasmid pNLX.luc.R- was used to generate LRT standard curves while 
pUC19.2LTR was used for 2-LTR circles [216]. The integration standard was prepared 
by infecting HeLa cells at relatively low multiplicity of infection with the pHI-puro 
transfer vector [219], passage for two weeks in 2 µg/ml puromycin to permit loss of 
unintegrated HIV-1 DNA forms, and extraction of total DNA using the QIAamp DNA 
Mini Kit. Two-fold dilutions of infected cell DNA were mixed with complementary 
amounts of DNA prepared from uninfected HeLa cells to form the standard curve. Two-
fold dilutions of uninfected cell DNA were used as the standard for β-globin. 
 QPCR primers and probes were: MH531, MH532, and MH535 for LRT [51]; 2-
LTR circle junction [224]; AE3014, AE1066, AE3013, AE990, and AE995 for Alu-PCR 
[223,225]; and β-globin+ and β-globin- for HeLa genomic DNA [65]. SYBR green was 
used to measure β-globin amplification. 
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Abstract 
 Lentiviruses can infect non-dividing cells, and various cellular transport proteins 
provide crucial functions for lentiviral nuclear entry and integration. We previously 
showed that the viral CA protein mediated the dependency on cellular NUP153 during 
HIV-1 infection, and now demonstrate a direct interaction between the CA N-terminal 
domain and the phenylalanine-glycine (FG)-repeat enriched NUP153 C-terminal domain 
(NUP153C). NUP153C fused to the effector domains of the rhesus Trim5α restriction 
factor (Trim-NUP153C) potently restricted HIV-1, providing an intracellular readout for 
the NUP153C-CA interaction during retroviral infection. Primate lentiviruses and EIAV 
bound NUP153C under these conditions, results that correlated with direct binding 
between purified proteins in vitro. These binding phenotypes moreover correlated with 
the requirement for endogenous NUP153 protein during virus infection. Mutagenesis 
experiments concordantly identified NUP153C and CA residues important for binding 
and lentiviral infectivity. Different FG motifs within NUP153C mediated binding to HIV-
1 versus EIAV capsids. HIV-1 CA binding mapped to residues that line the common 
alpha helix 3/4 hydrophobic pocket that also mediates binding to the small molecule PF-
3450074 (PF74) inhibitor and cleavage and polyadenylation specific factor 6 (CPSF6) 
protein, with Asn57 (Asp58 in EIAV) playing a particularly important role. PF74 and 
CPSF6 accordingly each competed with NUP153C for binding to the HIV-1 CA pocket, 
and significantly higher concentrations of PF74 were needed to inhibit HIV-1 infection in 
the face of Trim-NUP153C expression or NUP153 knockdown. Correlation between CA 
mutant viral cell cycle and NUP153 dependencies moreover indicates that the NUP153C-
CA interaction underlies the ability of HIV-1 to infect non-dividing cells. Our results 
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highlight similar mechanisms of binding for disparate host factors to the same region of 
HIV-1 CA during viral ingress. We conclude that a subset of lentiviral CA proteins 
directly engage FG-motifs present on NUP153 to affect viral nuclear import. 
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Introduction 
Retroviruses integrate their reverse transcribed genomes into host cell 
chromosomes to provide a permanent vantage from which to amplify themselves for 
subsequent transmission. As the nuclear envelope physically separates the host 
chromosomes from the cytoplasm during interphase, retroviruses have evolved 
mechanisms to bypass this natural barrier to the nuclear compartment. The γ-retrovirus 
MLV is believed to await the dissolution of the nuclear envelope during mitosis, a 
mechanism that limits infection by this virus to actively dividing target cells 
[21,132,171]. Lentiviruses such as HIV-1 infect post-mitotic cell subtypes during the 
establishment of host systemic infection, and correspondingly harbor mechanisms to 
infect cells during interphase, likely circumventing the nuclear envelope by passing 
through the channel present in the NPC [22,226]. 
 The vertebrate NPC is a large ~ 120 MDa macrostructure, composed of ~ 30 
different proteins called nucleoporins (NUPs) that stack in rings of eight-fold symmetry 
to form the tubular pore as well as the attached cytoplasmic filaments and nuclear basket 
substructures [227,228]. Approximately one-third of the NUPs harbor domains rich in 
phenylalanine-glycine (FG) motifs, commonly observed as FxF, FxFG, or GLFG patterns 
[32]. These FG-rich domains line the central channel of the NPC, as well as the 
cytoplasmic and nuclear openings [229], and dictate the selective passage of 
macromolecules through the pore; small molecules are able to passively diffuse, while 
molecules greater than ~ 9 nm in diameter need to be ferried by specialized carrier 
proteins capable of interacting with the FG-based permeability barrier [230]. 
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 The HIV-1 nucleoprotein substrate for proviral integration, called the PIC, is 
estimated at ~ 56 nm in diameter [79], and thus requires active translocation into the 
nucleus. While initial studies suggested that HIV-1 IN, MA, and Vpr proteins, as well as 
a triple-stranded DNA structure of the reverse transcribed genome called the DNA flap, 
were key viral elements required for PIC nuclear import, subsequent studies found none 
of these factors to be essential [173]. Contrastingly, the viral CA protein was shown to be 
the major viral determinant for infecting non-dividing cells [57,116]. Various host 
proteins have also been shown to play roles in HIV-1 nuclear import, with perhaps the 
most promising candidates emerging from a series of genome-wide RNAi screens; 
factors identified in more than one of these screens include transportin-3 (TNPO3 or 
TRN-SR2), NUP358, and NUP153 [28,29,141]. We have been particularly interested in 
NUP153, which plays an important CA-dependent role in HIV-1 PIC nuclear import 
[177,231]. 
 NUP153 is a FG nucleoporin that predominantly locates to the nuclear side of the 
NPC and exchanges dynamically with a nucleoplasmic population [181]. While NUP153 
is anchored to the nuclear rim of the NPC through its N-terminal domain [156], its C-
terminal FG enriched domain (referred to as NUP153C herein) is natively unfolded and 
highly flexible [162]. The ~ 200 nm long NUP153C potentially reaches through to the 
cytoplasmic side of the NPC channel [164], shifting in spatial distribution in a transport-
dependent manner [163,165]. Human NUP153C contains 29 FG motifs (FxF, FG, and 
FxFG patterns), which provide a vital role in NUP153-mediated nucleocytoplasmic 
transport [166,167,185]. 
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 While numerous studies have demonstrated the functional significance of CA for 
HIV-1 nuclear import and integration, the mechanistic details for these connections are 
incompletely understood. Retroviral CA proteins are composed of two α-helical domains, 
the N-terminal domain (NTD) and C-terminal domain (CTD), separated by a short 
flexible linker. CA multimerizes into hexameric arrays during particle maturation, while 
twelve interspersed pentamers dictate the overall shape of the condensed viral core [40-
43]. While relatively intact cores enter the cell upon viral-cell membrane fusion, little if 
any CA remains associated with the PIC within the nucleus [56,74,75,77,81]. The precise 
location and mechanism of CA core disassembly remains controversial: while initial 
steps of core uncoating are tied to reverse transcription [45], subsequent events may 
involve binding to host proteins. This may involve CypA and the NUP358 cyclophilin 
homologous domain (CHD), both of which bind the cyclophilin binding loop protruding 
from the top of the CA NTD [232,233], or CPSF6, which binds a hydrophobic pocket 
[234] located between α-helices 3 and 4 within the NTD. The small molecule PF-
3450074 (PF74), which inhibits HIV-1 infection by destabilizing incoming CA cores, 
also engages this same pocket [235]. CA-containing protein complexes have been 
observed alongside the nuclear envelope [80], suggesting that the ultimate steps of core 
uncoating may occur at the nuclear periphery and/or during PIC nuclear transport. 
 Here, we find that the CA proteins from numerous lentiviruses, including HIV-1 
and EIAV, directly bind NUP153C, with subsequent mapping demonstrating the 
importance of individual FG-motifs themselves. A panel of HIV-1 CA mutants highlights 
the importance of side-chains lining the CA NTD helix 3/4 hydrophobic pocket, and 
competition with both CPSF6 and PF74 support this as the site of NUP153C binding. 
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Correlation between NUP153 binding and dependence on endogenous NUP153 
expression additionally support the relevance of this interaction during infection. HIV-1 
CA mutant viruses N57A and N57D were defective for NUP153C binding and acutely 
sensitive to the arrest of the cell-division cycle, with a significant correlation between cell 
cycle and NUP153 dependencies observed among an expanded set of CA mutant viruses. 
Our data support a model whereby partially uncoated cores directly engage NUP153 FG-
motifs within the NPC to affect HIV-1 PIC nuclear import. 
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Results 
 
NUP153C binds the NTDs of a subset of retroviral CA proteins 
As we previously found CA to be the dominant viral determinant of the 
requirement for NUP153 during HIV-1 infection [231], we tested whether a physical 
interaction between NUP153 and HIV-1 CA exists. Our initial assay utilized a 
recombinant viral fusion protein consisting of HIV-1 CA and nucleocapsid (NC) proteins, 
which when assembled in vitro in the presence of high salt and single stranded nucleic 
acid forms large tube-like structures that readily pellet through cushions of sucrose [40]. 
In this way, CA-interacting proteins can co-sediment with the tube structures [122,177]. 
Full length or various fragments of HA-tagged NUP153 expression constructs were 
transfected into 293T cells, and the resulting proteins were tested for their ability to co-
sediment with CA-NC assemblies. Full-length NUP153 (residues 1-1475) pelleted 
through the sucrose cushion in a CA-NC dependent manner (Figure 3-1A and 3-1B). 
The NUP153 N-terminal domain (residues 1-650) failed to bind CA-NC under conditions 
that supported efficient NUP153C (residues 896-1475) binding. The C-terminal NUP153 
deletion mutant comprised of residues 1-1198 failed to bind, confirming the importance 
of the NUP153 FG-repeat domain in binding, and mapping the interaction to residues 
1199-1475 of the full length protein. 
We addressed whether the NUP153–CA-NC interaction was the result of direct 
protein binding through the use of purified, recombinant NUP153 protein. We attempted 
to express full-length NUP153 fused to glutathione S-transferase (GST) in bacteria, but 
despite extensive effort, were unable to define conditions that yielded usable quantities of  
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Figure 3-1. NUP153C directly binds the HIV-1 CA N-terminal domain. (A) Schematic of 
NUP153 protein, with residue numbers of domain boundaries indicated. (B) Full length or 
truncated fragments of HA-tagged NUP153 extracted from 293T cells were tested for binding to 
HIV-1 CA-NC. Pelleted proteins were resolved by SDS-PAGE and visualized by western blotting 
with anti-HA antibody 3F10 (top), or by Coomassie stain (bottom). Input, 20% of binding 
reaction. CA-NC was included in the binding reactions as indicated. (C) Recombinant, tag-free 
NUP153C and GST purified from E. coli were similarly tested for binding to CA-NC; proteins 
were detected with Coomassie stain. (D) Recombinant NUP153C pulled down with full length 
his-tagged wild-type (WT) or W184A/M185A HIV-1 CA, and detected with Coomassie stain. (E) 
Recombinant NUP153C pulled down with his-tagged CAN, and detected with Coomassie stain. 
Each experiment was repeated at least 3 times, with a single representative result shown. 
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GST-NUP153 protein. Based on our preliminary binding data (Figure 3-1B), we instead 
expressed and affinity purified GST-NUP153C. NUP153C was liberated from the GST tag 
by site-specific proteolysis, with the remaining CA binding studies utilizing tag-free 
NUP153C protein. Approximately 40% of the input recombinant NUP153C protein was 
recovered during co-sedimentation under conditions where binding of a negative control 
GST protein was undetected (Figure 3-1C). To test whether NUP153C binds CA in the 
absence of NC and nucleic acid, his-tagged HIV-1 CA expressed and purified from E. 
coli was utilized in Ni-nitrilotriacetic acid (NTA) pulldown assays. Approximately 30% 
of input NUP153C was pulled down by his-tagged HIV-1 CA protein. Notably, this 
interaction is likely independent of CA oligomerization, as double mutant 
W184A/M185A CA, which is unable to dimerize and form higher-ordered assemblies 
[236], pulled-down comparable amounts of NUP153C (Figure 3-1D). The isolated CA 
NTD (CAN) was expressed as a his-tagged protein and purified to next probe the binding 
region within HIV-1 CA; CAN pulled down ~ 30% of input NUP153C protein (Figure 3-
1E). Although these data do not quantitatively address potential CA oligomerization-
based affects on NUP153C binding, the relatively robust interaction with CAN suggests 
that NUP153 may efficiently engage monomeric CA during HIV-1 infection. 
The preceding results established a direct interaction between NUP153 and HIV-1 
CA proteins in vitro. We next examined whether an assay could be constructed to 
visualize the interaction in the context of HIV-1 infection. We scored for potential 
intracellular interaction by relying upon the potent capability of rhesus Trim5α 
(rhTrim5α) to inhibit HIV-1 infection. RhTrim5α is a cytoplasmically localized 
restriction factor, capable of blocking HIV-1 infection at an early post-entry step [121].  
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Figure 3-2. Restriction of HIV-1 infection by Trim5-NUP153C fusion proteins. (A) Schematic 
of Trim-NUP153C fusion and control constructs. Color code: Trim5 RBCC, brown; rhTrim5α 
SPRY, auburn; HA-tag, blue; NUP153C, orange. (B) Western blot of HOS cells stably transduced 
with HA-tagged Trim-NUP153C fusion or control constructs, detected with antibody 3F10. (C) 
Western-blot detection of Trim-NUP153C fusion proteins with anti-HA monoclonal antibodies 
3F10 and 16b12. Antibody 3F10 detects full-length Trim-NUP153C-HA whereas antibody 16b12 
more faithfully detects full-length Trim-HA-NUP153C. (D) Infectivity of various doses of HIV-1 
(left) or MLV (right) GFP reporter viruses on HOS cells stably expressing various Trim-based 
constructs. The results are an average of two experiments, with error bars denoting standard error. 
Asterisks in panels B and C mark bands that correspond to the expected mobilities of full length 
Trim-NUP153C constructs.
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While the C-terminal B30.2 (SPRY) domain recognizes patterns present on the surface of 
retroviral CA cores [237,238], the N-terminal RING, B-box 2, and coiled coil (RBCC) 
effector domains block infection by eliciting a combination of inhibitory activities, 
including premature disassembly of the viral core [122], proteasomal targeting [123], and 
triggering of innate immune signaling [239]. Both naturally occurring, as well as 
artificially engineered variants of Trim5 have been discovered wherein the SPRY domain 
is replaced by heterologous coding sequences, retaining viral restriction while changing 
the method by which the viral core is recognized [233,240,241]. In this vein we tested for 
intracellular recognition between NUP153C and HIV-1 CA by replacing the SPRY 
domain of rhTrim5α with NUP153C, concomitantly introducing either an internal- or C-
terminal HA epitope tag to enable detection of the fusion proteins by western blotting 
(Figure 3-2A). These constructs, as well as control constructs encoding only the epitope-
tagged rhTrim5 RBCC or NUP153C, were stably introduced into human osteosarcoma 
(HOS) cells (Figure 3-2B). While a single species of C-terminally HA tagged Trim-
NUP153C of the expected molecular weight was detected by western blot, the internally 
tagged construct revealed the protein susceptible to degradation, with the full-length 
protein representing only a minority of the expressed products at steady state (Figure 3-
2B and 3-2C). Regardless, Trim-NUP153C expressing cells potently restricted HIV-1 
infection, yielding consistent 5-10 fold reductions in viral titer (Figure 3-2D). The 
combination of both rhTrim5 RBCC and NUP153C domains was necessary, as neither 
domain expressed alone inhibited HIV-1 infection. Knockdown of endogenous NUP153 
acutely attenuates HIV-1 infection with little or no effect on MLV [231]. Importantly, the 
observed attenuation of HIV-1 infection by Trim-NUP153C expression was specific, as  
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Figure 3-3. Trim-NUP153C localizes to the cell cytoplasm and restricts HIV-1 reverse 
transcription. (A) Immunofluorescence confocal microscopy of HOS cells transduced with 
empty vector or the indicated HA-tagged construct. Hoescht 33342 stains DNA and therefore 
highlights cell nuclei. (B) Fractionation of rhTrim5α-HA, Trim-HA-NUP153C, and HA-NUP153C 
expressing cells. Gels were probed with antibodies against the HA tag (top panels), histone H3, α-
tubulin, or NUP62 (bottom panels). Cytoplasmic α-tubulin and nucleus-associated NUP62 and 
histone H3 marker proteins were predominantly found in fractions 1 and 3, respectively. 
Asterisks mark bands that correspond to the expected mobilities of full length constructs. (C-E) 
Levels of R-U5 DNA synthesis (early reverse transcripts) (C), U5-gag DNA synthesis (late 
reverse transcripts) (D), and 2-LTR circle formation (E), in cells transduced with empty vector, 
rhTrim5α-HA, or Trim-HA-NUP153C expressing constructs at 1, 6, 24, and 48 h post HIV-1 
infection, as detected by qPCR. Results (averages of three experiments, with error bars denoting 
standard error) were normalized to levels of peak DNA amplification, which was set at 100%. (F) 
Corresponding infectivity of GFP reporter viruses, measured 48 h post infection. Data were 
normalized to infectivity in cells transduced with empty expression vector. Results are an average 
of three experiments, with error bars denoting standard error.
70 
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infection by an MLV reporter virus was unaffected (Figure 3-2D). Similar to parental 
rhTrim5α, Trim-NUP153C located to the cell cytoplasm (Figure 3-3A and 3-3B) and 
prevented HIV-1 from completing reverse transcription (Figure 3-3C-F), suggesting that 
it likely recognizes the HIV-1 CA core in the cytoplasm shortly after viral entry. We 
conclude that although NUP153C in the context of the Trim5 protein likely engages HIV-
1 CA earlier than endogenous NUP153 protein, the novel fusion nonetheless affords the 
analysis of the NUP153-CA interaction in the context of HIV-1 infection. Due to the 
marginally greater level of restriction imparted by the internally tagged construct, the 
Trim-HA-NUP153C variant was used in subsequent experiments. 
The readout for intracellular CA core recognition was further validated by 
subjecting a panel of divergent retroviral reporter viruses to Trim-NUP153C inhibition. 
Primate lentiviruses SIVmac, SIVagmSab, SIVagmTan, and HIV-2 were similarly 
sensitive to Trim-NUP153C inhibition (Figure 3-4A). Though EIAV was also sensitive, 
not all lentiviruses were: neither bovine immunodeficiency virus (BIV) nor FIV was 
inhibited by Trim-NUP153C. The more distantly related α-retrovirus RSV was also 
unresponsive. To correlate the results of Trim-mediated restriction of virus infection to 
direct protein binding, a subset of the sensitive (EIAV) and nonresponsive (MLV and 
FIV) CAN proteins were purified following their expression in bacteria. EIAV CAN 
bound NUP153C as efficiently as HIV-1 CAN, whereas binding to either MLV or FIV 
CAN was significantly less efficient (P < 0.01) (Figure 3-4B and 3-4C). Reliance on 
NUP153 during retroviral infection was compared with CA-NUP153C binding (Figure 3-
4A) by correlating percent infectivity in the face of NUP153 knockdown [231] (repeated 
here using HOS cells; Figure 3-4D).  
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Figure 3-4. Diverse lentiviruses bind NUP153C. (A) Transduction efficiencies of retroviral GFP 
reporter viruses in Trim-NUP153C expressing cells normalized to infection in mock transduced 
cells, which were set to 100%. Results are the geometric mean of 4 experiments, with error bars 
denoting 95% confidence intervals. (B) HA-NUP153C expressed in 293T cells was pulled down 
by the indicated his-tagged retroviral CAN proteins. Captured proteins resolved by SDS-PAGE 
were western blotted with antibody 3F10 alongside a standard curve of input protein. The results 
are an average of 5 experiments, with error bars denoting 95% confidence intervals. A 
representative western blot is shown. (C) SYPRO Ruby detection of retroviral CAN pull-down of 
purified NUP153C. The results are an average of two experiments, with error bars denoting 
standard error. A representative western blot is shown. (D) (left) Retroviral infectivities in HOS 
cells knocked down for NUP153 expression as compared to cells treated with a non-targeting 
siRNA control [231]. The results are the geometric mean of at least 4 experiments, with error bars 
denoting 95% confidence intervals. (right) Western blot detection of control or NUP153 
knockdown HOS cells with antibody mab414. (E) Scatter plot comparing relative retroviral 
infectivities under each condition. 
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The resulting Spearman rank coefficient of 0.673 was statistically significant (P = 0.039) 
(Figure 3-4E). 
 
FG motifs within NUP153 dictate CA binding 
Mutations within NUP153C were made to decipher the components of NUP153 
critical for binding. As the HIV-1 restriction assay was higher throughput than the 
expression and purification of separate NUP153C proteins, we first engineered mutations 
within the Trim-NUP153C fusion construct. Since the starting fusion construct contained 
the entire ~ 580 amino acid NUP153C, we generated cell lines stably expressing Trim 
fusion proteins with roughly quarter-size deletions of NUP153C, and determined the 
extent to which these constructs inhibited HIV-1 and EIAV infection, using MLV and 
FIV as negative controls (Figure 3-5A and 3-5B). Relative levels of HIV-1 and EIAV 
infection were compared to ease the interpretation of results to Trim-NUP153C mediated 
restriction; parental Trim-NUP153C yielded an HIV-1 to EIAV infectivity ratio of ~ 0.41 
(Figure 3-5B). Deletion of residues 896 to 1045 at the N-terminus of NUP153C resulted 
in a construct that potently inhibited HIV-1 infection to a level ~ 8 fold greater than the 
full-length construct, yet lost the ability to inhibit EIAV, yielding an HIV-1 to EIAV 
infectivity ratio of ~ 0.01 (Figure 3-5B). Contrastingly, deletion of C-terminal residues 
1350 to 1475 resulted in a protein still capable of inhibiting EIAV infection to a level 
comparable to the full-length construct, yet incapable of inhibiting HIV-1 infection 
beyond the level of the control viruses, resulting in an infectivity ratio of ~ 4.70. These 
effects were specific to sequences deleted in the preceding constructs, as neither internal 
deletion noticeably perturbed the original Trim-NUP153C restriction pattern; both  
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Figure 3-5. Different NUP153C sub-regions mediate Trim-NUP153C restriction of EIAV 
versus HIV-1 infection. (A) To-scale schematic of NUP153C sequences encoded in various 
Trim-NUP153C constructs. Red lines represent boundaries of quarter-sized NUP153C sub-regions, 
while black lines denote the locations of FG motifs. (B) Infectivity of retroviral GFP reporter 
viruses on HOS cells stably expressing full-length or quarter-deleted Trim-NUP153C constructs, 
normalized to infection in mock transduced cells. Data represent the geometric mean of 5 
experiments, with error bars denoting 95% confidence intervals. HIV-1 to EIAV ratios of 
infectivity are shown, with associated standard error. (C) Western blot of HOS cells stably 
transduced with Trim-NUP153C fusion constructs detected with antibody 16b12. Asterisks denote 
bands corresponding to the expected mobilities of full length or mutated Trim-NUP153C 
constructs. 
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constructs displayed the same slight advantage to inhibit HIV-1 infection over EIAV, 
with HIV-1 to EIAV infectivity ratios similar to the full-length construct. Western 
blotting confirmed that each deletion construct was expressed at roughly similar levels 
(Figure 3-5C). The mapping of the HIV-1 binding determinant on NUP153C to residues 
1350-1475 by Trim-mediated restriction notably coincides with our preliminary 
identification of the region C-terminal to residue 1198 using CA-NC tubes and HA-
tagged NUP153 deletion constructs (Figure 3-1B). 
We next focused on the initial quarter of NUP153C for its importance in 
mediating restriction of EIAV infection. Stable cell lines expressing only the first quarter 
of NUP153C fused to the Trim RBCC, as well as smaller derivatives of the NUP153C 
sequence, were generated (Figure 3-6A). Residues 896-949, which yielded the smallest 
construct capable of restricting EIAV infection (Figure 3-6B), harbored only two of the 
29 FG motifs present within NUP153C. The importance of these FG motifs in mediating 
EIAV restriction was tested by substituting four consecutive alanine residues for each 
corresponding FKFG sequence. The combination octa-alanine 903A/924A Trim-
NUP153C mutant construct lost its ability to inhibit EIAV infection despite being 
expressed at a level equal to or greater than unmodified Trim-NUP153C (Figure 3-6B 
and 3-6C). The 903A/924A mutant moreover retained potent HIV-1 restriction. Separate 
mutation of each motif revealed 924-FKFG-927 as the dominant FG sequence for 
mediating EIAV restriction. 
Sequence components of NUP153C that mediated restriction of HIV-1 infection 
were investigated next. Attempts to recover cells expressing the responsible C-terminal 
quarter of NUP153C (residues 1350-1475) fused to Trim RBCC were unsuccessful. We  
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Figure 3-6. The importance of FG motifs for Trim-NUP153C mediated inhibition of HIV-1 
and EIAV infection. To-scale schematics (A and D), normalized infection data (B and E), and 
western blotting (C and F) as described for Figure 3-5. Infection data are the geometric mean of 
at least 4 experiments, with error bars denoting 95% confidence intervals. Inverted grey triangle 
(panels A and D) denotes area of missense mutation. 
77 
instead undertook the alternative strategy to internally delete segments of residues 1350-
1475 from the full-length Trim-NUP153C construct (Figure 3-6D). Deletion of residues 
1410-1447 selectively diminished inhibition of HIV-1 without affecting EIAV, yielding 
an increased HIV-to-EIAV infectivity ratio of 2.7, while deletion of residues 1350-1410 
did not drastically alter the ratio from that observed with the full length construct (Figure 
3-6E and 306F). As residues 1410-1447 contained only one FxFG and one FxF motif, 
these were mutated to alanine residues, initially in the context of the ∆1350-1410 
construct. Combinatorial alteration of both tetra- and tri-peptides reduced restriction of 
HIV-1 without significantly affecting EIAV restriction (HIV-1/EIAV infectivity ratio = 
2.29). Separate mutation showed this effect was largely, if not entirely due to 1415-
FTFG-1418, and the 1415A mutation largely prevented restriction of HIV-1 in the full-
length construct as well (infectivity ratio = 2.17). Combined, these results highlight the 
importance of FG motifs for Trim-NUP153C mediated restriction of HIV-1 and EIAV 
infection. Moreover, different FG motifs appear to selectively recognize HIV-1 versus 
EIAV CA proteins. 
We subsequently tested for Trim-NUP153C FG motif recognition of EIAV and 
HIV-1 CA proteins in vitro. HA-tagged NUP153C or analogous quarter deleted fragments 
expressed in 293T cells were used as bait for pull-down by various his-tagged retroviral 
CAN proteins (Figure 3-7A). The construct lacking residues 1045-1198 was expressed 
far less than the other constructs, and was not interpreted. As expected (Figure 3-4B), 
none of the constructs bound MLV CAN to levels greater than those observed with beads 
alone. Consistent with the results from Trim-NUP153C restriction, the protein lacking 
residues 1350-1475 was selectively bound less well by HIV-1 CAN. Contrastingly, EIAV  
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Figure 3-7. FG motifs determine NUP153C binding to HIV-1 CAN. (A) Pull-down of full-
length or quarter deleted HA-NUP153C by HIV-1, EIAV, or MLV CAN proteins, detected with 
antibody 3F10. (B) Pull-down of WT NUP153C, FG-motif tetra-alanine mutant 1415A, or 
combinatorial 7xFG/A mutant by beads alone (none, grey), HIV-1 (red), MLV (blue), or EIAV 
(green) CAN proteins, as detected by western blot with antibody 3F10. Results are an average of 
at least 4 experiments, with error bars denoting standard error. (C) Purified NUP153C (black 
circles, solid line), NUP153C∆1350-1475 (purple triangles, fine dotted line), and 
NUP153C7xFG/A (brown diamonds, coarse dotted line) were incubated with various 
concentrations of HIV-1 CAN and a constant amount of Ni-NTA beads. Data points represent the 
mean and standard error of at least three experiments, fit with non-linear regression curves. The 
dissociation constant of NUP153C binding was calculated by averaging concentrations of half-
maximal binding for 5 individual experiments, with associated standard error. (D) Sedimentation 
of WT NUP153C, FG-motif tetra-alanine mutant 1415A, combinatorial 7xFG/A mutant, or 
NUP153C∆1350-1475 after incubation with buffer alone or assembled CA-NC. Results are an 
average of 6 experiments, with error bars denoting 95% confidence intervals. Representative 
western blotting results are shown. 
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(Figure 3-7, continued) 
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CAN bound all of the fragments tested, including the fragment that lacked residues 896-
1045. 
We further tested whether HIV-1 CAN binding was traceable to specific FG 
motifs. HA-NUP153C containing the 1415-FTFG-1418 tetra-alanine replacement bound 
HIV-1 CAN essentially as well as the unmutated fragment (Figure 3-7B). Since we 
observed strongly diminished binding when the last quarter of HA-NUP153C was deleted 
(Figure 3-7A), we next mutated all 7 of the FG motifs within this segment to alanines 
(HA-NUP153C7xFG/A). The combination of these mutations selectively abrogated 
binding of HA-NUP153C to HIV-1 CAN; importantly, effective binding of the mutant 
protein to EIAV CAN was retained (Figure 3-7B). Decreased ∆1350-1475 and 7xFG/A 
mutant binding to HIV-1 CAN was also observed with purified NUP153C proteins. HIV-1 
CAN bound purified NUP153C (0.5 µM) in a dose-dependent manner, revealing a 
corresponding Kd of ~ 28.3 µM at half-maximal saturation (Figure 3-7C). Although CAN 
displayed some affinity for NUP153C∆1350-1475 and NUP153C-7xFG/A, the shapes of 
these linear response curves were notably different from the unmutated protein, and half-
maximal saturation was not reached under these assay conditions. 
We hypothesized that differing states of CA multimerization might contribute to 
the partially overlapping specificities observed in the CAN pull-down (Figure 3-7A and 
3-7B) versus Trim-NUP153C restriction (Figure 3-6E) assays. To test this, assembled 
CA-NC tubes were substituted for monomeric CAN protein. Under these conditions, both 
the NUP153C-7xFG/A and 1415A mutant proteins displayed significantly diminished 
binding, similar to the effect observed for the ∆1350-1475 deletion (P < 0.01) (Figure 3-
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7D). These findings seemingly agree with the results of the Trim-NUP153C mediated 
restriction assays (Figure 3-5B and 3-6E). 
 
Side-chains proximal to a common hydrophobic pocket in HIV-1 CAN mediate 
NUP153C binding 
We and others previously observed that various CA mutant viruses exhibit altered 
sensitivity to NUP153 knockdown [177,231]. We next characterized an expanded set of 
CA mutant viruses for altered sensitivity to Trim-NUP153C restriction. Mutants were 
selected based on prior descriptions of pre-integrative defects during HIV-1 infection. 
Alteration of CA residue(s) Pro38, Glu45, Thr54/Asn57, or Gln63/Gln67 can effect core 
stability [45,57,119,120], whereas Thr54, Asn57, Lys70, Asn74, Gly89, Pro90, Ala92, 
Gly94, and Thr107 mutants can alter dependencies on various host proteins, including 
CPSF6, TNPO3, NUP358, CypA, or NUP153 [177,187,191,231,233,234,242,243]. As a 
number of these mutants exhibit drastically diminished overall levels of infectivity 
(Figure 3-8A), an unrelated IN mutant virus (D167K), which infects cells at ~ 8% of the 
level of wild-type (WT) HIV-1 [244], was included to control for our ability to 
reproducibly measure restriction at reduced viral titers. While the IN mutant virus was as 
sensitive as the WT virus to Trim-NUP153C restriction, a number of CA mutant viruses 
exhibited significantly reduced susceptibility (P < 0.001) (Figure 3-8B). Included among 
these were CypA and NUP358 CHD binding mutants G89V and P90A [187,233], as well 
as mutants E45A, T54A/N57A, N57A, N57D, Q63A/Q67A, Q67A, K70R, and N74A. 
As these CA mutant viruses could resist Trim-NUP153C restriction for any 
number of reasons, we tested for direct binding defects by pulling down NUP153C with  
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Figure 3-8. HIV-1 CA mutant-NUP153C binding and sensitivity to Trim-NUP153C 
restriction. (A) Equal RTcpm of WT and HIV-1 mutant viruses plated on HOS cells, with 
resulting infectivities normalized to WT virus. (B) Percent infectivity of viruses in Trim-
NUP153C expressing HOS cells, normalized to mock transduced control cells. Graphs show the 
mean of at least 5 experiments, with error bars denoting 95% confidence intervals. (C) Purified 
NUP153C pull-down by WT or the indicated mutant his-tagged HIV-1 CAN protein, with 
recovered proteins resolved by SDS-PAGE and detected by SYPRO Ruby stain. Results are an 
average of 5 experiments, with error bars denoting 95% confidence intervals. A representative 
staining result is shown. The dotted line highlights the level of NUP153C binding to WT CAN 
protein. (D) HA-NUP153C in 293T cell lysates pulled-down by WT or various mutant his-tagged 
HIV-1 CAN proteins, with recovered protein resolved by SDS-PAGE and detected by 3F10 and 
anti-his antibodies. Results are an average of 4 experiments, with error bars denoting standard 
error. A representative western blot result is shown. The dotted line highlights the level of HA-
NUP153C binding to WT CAN protein. 
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correspondingly purified CAN mutant proteins. Residue Asn57 was critical for binding, 
as mutant proteins T54A/N57A, N57A, and N57D were strongly diminished in their 
abilities to pull down NUP153C (Figure 3-8C). Although not critical for binding, both 
Lys70 and Asn74 appeared to participate: mutation of Lys70 to arginine diminished 
binding while mutation to alanine enhanced binding; contrastingly, mutation of Asn74 to 
alanine diminished binding, while mutation to aspartic acid enhanced binding to 
NUP153C. The Q63A/Q67A mutation marginally diminished binding by ~ 1.3 fold. This 
binding hierarchy was also observed for HA-NUP153C protein expressed in mammalian 
cells, with Asn57 again proving key for the interaction, and mutants K70A and N74D 
yielding hyper-binding activity (Figure 3-8D). Overall, CA mutant viral sensitivities to 
Trim-NUP153C restriction correlated well with CAN mutant binding to NUP153C protein 
in vitro (Figure 3-9A). 
As we predict that mutant viruses that require NUP153 for infection also bind 
NUP153C, we compared the sensitivities of CA mutant viruses to NUP153 knockdown 
with their susceptibility to Trim-NUP153C mediated restriction. We observed that CA 
mutant viruses that require endogenous NUP153 for infection were also sensitive to 
Trim-NUP153C mediated restriction. A strong correlation supported this relationship 
across the entire panel of CA mutant viruses (Figure 3-9B). This included NUP153C 
loss-of-binding mutants T54A/N57A, N57A and N57D, which retained approximately 
85%, 102% and 58% of their infectivity, respectively, upon NUP153 knockdown. 
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Figure 3-9. Comparison of HIV-1 CA mutant-NUP153C sensitivity to Trim-NUP153C 
restriction with binding to NUP153C, or sensitivity to NUP153 depletion. (A) Scatter plot of 
NUP153C recovery in pull-down assays (Figure 3-8C) compared to percent infectivity in Trim-
NUP153C expressing cells (Figure 3-8B). Points are color-coded based on NUP153C binding 
phenotype: grey, not significantly different from WT; white, significantly decreased from WT; 
black, significantly increased from WT. (B) Scatter plot of normalized infectivity of CA mutant 
viruses in Trim-NUP153C expressing cells compared to the average infectivity of three 
experiments when endogenous NUP153 was knocked down. The comparison exhibited a 
significant Spearman rank correlation (P < 0.0001). Points are color-coded as in panel C, except 
for CA mutants not tested for binding, which are denoted with “x” symbols. 
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The NUP153C binding site overlaps with those for PF74 and CPSF6 
Residues Asn57, Lys70, and Asn74, highlighted in our binding assays, surround a 
hydrophobic pocket within CAN formed by α helices 3 and 4, and this pocket has been 
shown to be the binding site of the small molecule inhibitor PF74 [235] (Figure 3-10A). 
To probe potentially similar binding modes, we tested whether PF74 could compete for 
HA-NUP153C binding to CAN (Figure 3-10B). PF74 indeed competed for binding to 
CAN in a dose-dependent manner, with an IC50 of ~ 13.6 µM. While PF74 binds WT and 
N74D CAN proteins similarly [234], the small molecule was less effective at competing 
for HA-NUP153C binding to N74D CAN, yielding an IC50 of 145.3 µM, perhaps due to 
the increased binding observed between NUP153C and N74D CAN (Figure 3-8C and 3-
8D). PF74 does not bind K70A mutant CAN [234], and accordingly did not compete for 
HA-NUP153C binding to this mutant protein (Figure 3-10B). 
This same pocket also engages the mRNA splicing cofactor CPSF6 
[177,234,240], which was first implicated in HIV-1 biology by the ability for an 
exogenously expressed C-terminal truncation mutant CPSF6358 to restrict PIC nuclear 
import [177]. Though vastly differing molecules, co-crystal structures of PF74-CAN and 
CPSF6 (residues 313-327)-CAN complexes revealed that each exhibit nearly identical 
insertions of methyl benzyl residues (Phe321 in the case of CPSF6) within the helix 3/4 
pocket, in both cases forming two hydrogen bonds with the carboxamide side-chain of 
CA residue Asn57 (Figure 3-10A and 3-10C). Based on these observations, we tested 
whether purified NUP153C could compete with full-length CPSF6 protein for binding to 
CA. HA-tagged CPSF6 expressed in 239T cells was incubated with HIV-1 CA-NC tubes 
prior to centrifugation through a 20% sucrose cushion. CPSF6 pelleted only in the  
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Figure 3-10. NUP153C competes with molecules that bind the HIV-1 CAN hydrophobic 
pocket. (A) X-ray crystal structure (pdb: 2xde) of compound PF74 (yellow) bound to HIV-1 CAN 
(green). Critical CAN side-chains (labeled) are shown as sticks, with oxygen and nitrogen atoms 
colored red and blue, respectively. Hydrogen bonds are shown as black dashes, with distances 
labeled. The phenylalanine moiety in PF74 is indicated by the black arrow. (B) PF74 competition 
of HA-NUP153C binding to WT or mutant his-tagged HIV-1 CAN. Recovered HA-NUP153C was 
detected with antibody 3F10 and quantitated alongside a standard curve of serially diluted HA-
NUP153C-containing lysate. Baseline background signal observed with T54A/N57A CAN 
pulldown was subtracted, and all values were normalized to that of the DMSO control (2% 
DMSO final concentration in each sample). Results are an average of at least 2 experiments, with 
error bars denoting standard error. Representative western blotting results are shown. (C) X-ray 
crystal structure (pdb: 4b4n) of a peptide from CPSF6 (backbone carbon atoms shown as sticks in 
grey) bound to CAN (green) in the same orientation as in panel A. Side-chains and hydrogen 
bonds are represented as in panel A. The CPSF6 Phe321 side chain is indicated by the black 
arrow. (D) Binding of HA-tagged, full-length CPSF6 protein in 293T cell extract to HIV-1 CA-
NC protein, and competition with purified NUP153C or mutants thereof. Results of 5 experiments 
were normalized to the level of CPSF6 binding observed in the absence of competing factors, 
with error bars denoting standard error. 
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presence of CA-NC (Figure 3-10D). This interaction indeed required binding to the CAN 
hydrophobic pocket, as excess PF74 counteracted it. We additionally observed that co-
incubation with purified NUP153C significantly diminished CPSF6 binding (P < 0.0001) 
by ~ 7 fold as compared to the level observed in the absence of competing factors. This 
competition was specific, as NUP153C mutants ∆1350-1475 and 7xFG/A, both of which 
exhibit greatly diminished binding to CA-NC (Figure 3-7), were significantly less 
effective at competing for CPSF6 binding (P < 0.05) (Figure 3-10D). 
CA residues that mediate binding to NUP153C and CPSF6 were further analyzed 
by assessing CA mutant sensitivities to restriction by the artificial restriction factor Trim-
CPSF6358 (Figure 3-11A), a larger derivation of the Trim-CPSF6 fusion proteins 
previously tested [240]. Though conferring similar levels of restriction, far fewer of the 
CA mutant viruses were able to resist Trim-CPSF6358 inhibition (Figure 3-11B, red data 
points) compared to Trim-NUP153C (black points). CypA binding mutants G89V and 
P90A were partially resistant to Trim-CPSF6358 restriction, whereas N57A, N74A, and 
N74D in large part conveyed full resistance. The N57A and N74D changes were notably 
previously shown to prevent binding of CAN to the CPSF6 peptide [234]. Interestingly, 
changes at Asn57 and Asn74 conferred distinguishable resistance profiles to Trim-
NUP153C versus Trim-CPSF6358: both conservative N74D and non-conservative N74A 
changes rendered HIV-1 resistant to Trim-CPSF6358, while only N74A rendered the virus 
partially resistant to Trim-NUP153C (Figure 3-11B). Contrastingly, both conservative 
and non-conservative Asn57 changes prevented Trim-NUP153C recognition, while the 
conservative N57D mutant remained as sensitive to Trim-CPSF6358 restriction as the WT 
virus. 
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Figure 3-11. HIV-1 CA mutant sensitivities to Trim-NUP153C as compared with sensitivities 
to CPSF6358 and Trim-CPSF6358. (A) Western blot of HOS cells stably expressing Trim-
CPSF6358 or CPSF6358, detected with antibody 3F10. (B) CA mutant virus sensitivities to Trim-
NUP153C (black) and Trim-CPSF6358 (red), as compared to cells transduced with an empty 
vector. Results are an average of at least 3 experiments, with error bars denoting 95% confidence 
intervals. (C) Scatter plot of CA mutant sensitivities to NUP153 knockdown compared with 
sensitivities to inhibition by CPSF6358. (D) Percent infectivity of CA mutant viruses on CPSF6358 
expressing HOS cells compared to mock transduced cells. Results are the average of 3 
experiments, with error bars denoting standard error. 
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The breadth of CA mutants restricted by Trim-CPSF6358 in HOS cells appeared to 
contrast with prior results of CPSF6358-mediated restriction of HIV-1 in Hela cells, where 
many of the same CA mutations conferred resistance to inhibition [66]. We confirmed 
these phenotypes in HOS cells, where we observed that many additional CA mutant 
viruses resist CPSF6358-mediated restriction (Figure 3-11C). Many of the CA mutant 
viruses selectively resistant to CPSF6358 over Trim-CPSF6358 restriction were also 
insensitive to endogenous NUP153 knockdown, resulting in a moderate correlation 
between CA mutant sensitivities to CPSF6358 restriction and NUP153 knockdown 
(Figure 3-11D). 
PF74 destabilizes the structure of purified CA cores and can inhibit reverse 
transcription, which likely accounts for at least part of its antiviral activity [245]. We 
assessed whether PF74 could additionally antagonize NUP153C engagement by CA in the 
context of HIV-1 infection, given the caveat that we could not unambiguously correlate 
data from protein binding assays (Figure 3-10B) with effects from PF74-induced capsid 
destabilization in cells. PF74 exhibited dose-dependent inhibition of WT HIV-1 and 
N74D CA mutant viral infection, but had no effect on CA mutant T54A/N57A, which 
lacks the critical Asn57 side-chain necessary for PF74 binding [234] (Figure 3-12A, 
upper panel; results replotted below to reveal EC90 values under conditions of Trim-
NUP153C restriction). WT virus was noticeably less sensitive to PF74 in Trim-NUP153C 
expressing cells, with an EC90 of 5.65 µM as opposed to 0.65 µM in control cells (Figure 
3-12A). The competing effect of PF74 on Trim-NUP153C inhibition seemingly occurred 
between the concentrations of 0.1 and 1 µM (light green shading in Figure 3-12A), as the 
inhibition curves within the two cell lines were nearly  
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Figure 3-12. PF74 similarly counteracts HIV-1 in the face of Trim-NUP153C restriction and 
NUP153 knockdown. Mock transduced and Trim-NUP153C expressing (A) or non-targeting 
control and NUP153 knockdown (B) HOS cells were infected with equal RT-cpm of denoted 
viruses in the presence of various PF74 concentrations. Results are shown as infectivity 
normalized to vehicle only control cells (top), or vehicle only infection for each cell type (bottom) 
to calculate EC90 values. Dashed lines represent Trim-NUP153C or NUP153 knockdown results in 
panels A and B, respectively. Results are an average of at least 3 experiments, with error bars 
denoting standard error. Calculated EC90 values are displayed with standard error. 
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superimposable outside of these concentrations. N74D CA mutant virus also exhibited a 
shift in the PF74 EC90 concentration in Trim-NUP153C cells, though this occurred at 
higher PF74 concentrations than with the WT virus. Interestingly, an almost identical 
effect was observed with WT virus when PF74 was titrated onto NUP153 knockdown 
cells; the EC90 shifted from 0.54 µM to 5.41 µM, with the same window of 
concentrations likely accounting for the discrepancy in inhibition curves (Figure 3-12B). 
While the exact mechanism of NUP153 antagonism – direct, or indirect through the 
alteration of the state of CA multimerization – is difficult to discriminate, the nearly 
superimposable interference profiles of PF74 in Trim-NUP153C expressing and NUP153 
knockdown cells support the relevance of the Trim-NUP153C restriction assay as a 
surrogate readout for the engagement of endogenous NUP153 protein. 
 
An analogous pocket in EIAV CA mediates binding to NUP153C 
Retroviral CAN proteins exhibit remarkable similarity in secondary and tertiary 
structure despite marked differences in primary sequence [246,247]. With the exception 
of HIV-1 residue Gln67, the previously described polar residues flanking the helix 3/4 
hydrophobic pocket (Asn57, Lys70, and Asn74 in HIV-1) exhibit variability across 
divergent retroviruses (Figure 3-13A, yellow boxes). While HIV-2 and SIVmac only 
differ at these positions with Arg69 in place of HIV-1 Lys70, EIAV exhibits greater 
difference: Leu71 corresponds to HIV-1 Lys70, and EIAV Asp58 and Asp75 correspond 
to HIV-1 Asn57 and Asn74, respectively (Figure 3-13B). These differences may account 
for the resistance of EIAV to inhibition by PF74 (Figure 3-13C) and CPSF6358 [240], 
which we confirmed using HOS cells expressing Trim-CPSF6358 (Figure 3-13D). As  
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Figure 3-13. Mode of NUP153C binding to EIAV CA. (A) Alignment of residues corresponding 
to HIV-1 CA Leu56 through Asn74 among various retroviruses. Residues that significantly 
affected HIV-1 CAN binding with NUP153C are highlighted in yellow. (B) Alignment of HIV-1 
CAN (green, pdb: 3mge) and EIAV CAN (gray, pdb: 1eia), with side-chains surrounding the 
pocket shown as sticks. (C) Retroviral sensitivities to inhibition by PF74. Color codes: HIV-1, 
green; SIVmac, black; MLV, red; EIAV, orange; BIV, blue; FIV, purple. Results are an average 
of two experiments. (D) Retroviral sensitivities to inhibition by Trim-CPSF6358. Results are an 
average of 3 experiments. (E) Infectivity of RT-cpm matched EIAV GFP-reporter viruses 
carrying CA point mutations. Results are an average of 3 experiments. (F) Pull-down of purified 
NUP153C by EIAV point mutant CAN proteins. Results are an average of 2 experiments. (G) 
Sensitivity of EIAV CA point-mutant viruses to Trim-NUP153C. Results are an average of 4 
experiments. Error bars in each panel denote standard error. 
94 
Asp58 exhibits similar physiochemical properties as its HIV-1 Asn57 counterpart, we 
mutated this as well as residue Asp75 to test their contributions to NUP153C binding. 
Similar to HIV-1 mutant N57A, EIAV CA mutant D58A was poorly infectious (Figure 
3-13E), and the corresponding CAN protein was unable to pull down appreciable levels of 
NUP153C protein (Figure 3-13F). Contrastingly, EIAV CA mutant D75A behaved 
similar to WT EIAV (Figure 3-13E and 3-13F). The Trim-NUP153C sensitivities of 
these viruses corresponded with the binding profiles of their CAN proteins: D58A was 
completely insensitive to Trim-NUP153C mediated restriction, while D75A remained as 
sensitive as WT EIAV (Figure 3-13G). 
 
Comparison of NUP153 requirement and cell cycle dependence 
Changes at Asn57 in HIV-1 CA have previously been associated with cell cycle 
dependence: T54A/N57A infection was attenuated in both chemically arrested cell lines 
and non-dividing primary macrophages [57,117], and the N57A mutant virus was 
recently shown to lose infectivity upon chemical arrest of Hela cells [233]. We confirmed 
the importance of Asn57, as well as other previously observed cell cycle dependent 
phenotypes, with our panel of CA mutant viruses; alanine substitution of residue Glu45, 
Thr54, Asn57, or Gln67 rendered the virus significantly sensitive to growth arrest 
(Figure 3-14A and 3-14B). Notably, we found even the conservative N57D substitution 
rendered the virus as, if not more sensitive, than these mutants to growth arrest. A 
handful of CA mutant viruses have been described to be sensitive to cell cycle arrest in 
Hela cells in a CypA-dependent manner [117,118]. We found N57A and N57D CA 
mutant viruses to remain highly cell cycle dependent when the interaction with CypA 
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Figure 3-14. Association between NUP153 dependency and cell cycle independence. (A) 
Propidium iodide staining of HOS cells untreated (grey) or treated for 24 h with 5 µM Etoposide 
phosphate (red line). (B) Infectivity of CA mutant viruses in HOS cells arrested with 5 µM 
Etoposide phosphate, normalized to infectivity in control HOS cells. Error bars denote standard 
error of 4 experiments. (C) Scatter plot comparison of CA mutant sensitivities in cell cycle 
arrested HOS cells in the absence or presence of 5 µM CsA. Mutant viruses most sensitive to cell 
cycle arrest are indicated. (D to G) Scatter plots comparing sensitivities of mutant viruses to cell 
cycle arrest versus NUP153 knockdown (D), or restriction by Trim-NUP153C (E), CPSF6358 (F), 
or Trim-CPSF6358 (G). Spearman rank correlation coefficients and measures of significance are 
indicated. Data points for CA mutant viruses P38A, T54A, A92E, and G94D clustered with the 
WT virus within these panels, so their labels were omitted to aid legibility. 
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 was blocked by the addition of cyclosporine during infection (Figure 3-14C). 
Based on the coincident NUP153-insensitive and cell cycle dependent phenotypes of 
Asn57 mutant viruses, we tested the association between NUP153 requirement and cell 
cycle dependency in the context of our expanded panel of mutant viruses. We observed a 
moderately strong inverse correlation between requirement for NUP153 and cell cycle 
dependence during infection (Figure 3-14D). Notably, of the viruses tested in our panel, 
all of the ones that were cell cycle dependent were NUP153 independent. The correlation 
however was not absolute, as N74D, G89V, P90A, and T107N mutant viruses did not 
require NUP153 for infection yet remained cell cycle independent. There was a moderate 
correlation between cell cycle dependence and Trim-NUP153C resistance (Figure 3-
14E). We observed a moderate to low correlation between cell cycle dependence and 
CPSF6358 mediated restriction, and no correlation with Trim-CPSF6358 mediated 
restriction (Figure 3-14F and 3-14G). These results reveal that cell cycle dependence is 
associated with NUP153 independence, and that this relationship likely depends on CA-
NUP153 binding. 
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Discussion 
 
NUP153 FG motif binding within the CA helix 3/4 cavity 
 GFP-tagged NUP153 expressed in animal cell lysate was recently shown to co-
sediment with HIV-1 CA-NC tubes in vitro [248]. We confirmed this observation for 
HA-tagged protein, and extended it by using purified recombinant protein to demonstrate 
direct binding between the FG-enriched NUP153C and the HIV-1 CA NTD. Mutation of 
CA residue Asn57, Lys70, or Asn74, which each flank the hydrophobic pocket between 
CA α helices 3 and 4, perturb binding of NUP153C protein to HIV-1 CAN. Furthermore, 
NUP153C competes with PF74 and CPSF6 for binding, both of which engage the same 
pocket. Notably, co-crystal structures between HIV-1 CAN and the latter two molecules 
exhibit an almost identically situated benzyl ring within the hydrophobic cavity, with the 
amide nitrogen and carbonyl oxygens of this phenylalanine moiety each forming a 
hydrogen bond with the side chain of Asn57 [234] (Figure 3-10). This observation, in 
conjunction with our finding that FG motifs within NUP153C strongly contribute to 
binding with CAN, suggest that the phenylalanine moieties of specific FG motifs found in 
NUP153C likely take on a similar conformation during binding. We accordingly speculate 
that hydrogen bonding with Asn57 underlies the FG motif interaction, as both N57A and 
N57D mutations abrogated binding. While originally described to support CPSF6 binding 
[234], the high degree of amino acid conservation within this region of CA amongst 
primate lentiviruses likely also reflects the requirement for binding to NUP153 during 
virus infection [231].  
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Relevance of FG motif binding for NUP153 dependency during HIV-1 infection 
Supporting the relevance of the NUP153-CA interaction, both a divergent set of 
retroviruses and a targeted set of CA missense mutants exhibited significant correlations 
between CA binding to NUP153C – either tested in vitro or inferred through Trim-
NUP153C recognition – and requirement for endogenous NUP153 protein during 
infection (Figures 3-4 and 3-9). Notably, loss-of-binding CA mutant viruses 
T54A/N57A, N57A, and N57D infected cells independent of endogenous NUP153 
expression. The relationship between NUP153 binding and host factor requirement was 
consistent with PF74 sensitivity as well; while potentially mediated through an indirect 
effect on uncoating, PF74 interfered with Trim-NUP153C restriction at the same 
concentrations that it antagonized the inhibition of infection caused by NUP153 
knockdown (Figure 3-12). 
Woodward and colleagues reported that ectopically-expressed NUP153C protein 
imparted an approximate twofold defect on HIV-1 infection [98], a result we did not 
reproduce despite efficient NUP153C expression (Figure 3-2). By contrast, appending 
NUP153C to the RBCC domains of rhTrim5α resulted in potent HIV-1 restriction, 
allowing us to infer the results of NUP153C binding to the CA shell during virus 
infection. NUP153 has been shown to bind HIV-1 IN [98], and though we observed 
minimal binding (≤1% of input IN recovered by GST-NUP153C pull-down; Figure 3-
15), it was comparably weaker than our findings with HIV-1 CA (30-40% of input 
NUP153C recovered), and was less correlative with lentiviral requirement for endogenous 
NUP153 (Figure 3-4D) as FIV IN bound more robustly than HIV-1 IN to NUP153C in 
our hands (Figure 3-15). Thus, while NUP153 may bind more than one HIV-1  
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Figure 3-15. GST-NUP153C pull-down of HIV-1 and FIV IN. GST-NUP153C pulled-down an 
average of ~ 0.85 % of input his-tagged HIV-1 IN and ~ 5.55 % of input his-tagged FIV IN over 
3 experiments. A representative experiment is shown. Note preferential western blot detection of 
the FIV IN N-terminal his-tag over that of the HIV-1 tag.  
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determinant, our results are consistent with a direct interaction between NUP153C and 
viral CAN underlying the requirement for NUP153 during HIV-1 infection. 
 
Potentially degenerate binding of NUP153 FG motifs 
 Different FG motifs within Trim-NUP153C mediated restriction of EIAV versus 
HIV-1 infection (Figure 3-6). Contrastingly, correspondence to protein binding in vitro 
was less strict: NUP153C∆896-1045 effectively bound EIAV CAN, though this deletion 
variant could not inhibit EIAV as a Trim-fusion. The 1415-FTFG-1418 tetra-alanine 
mutant, which lost the ability to inhibit HIV-1 as a Trim-fusion, was little if at all reduced 
for pull-down by HIV-1 CAN, though alteration of all seven FG motifs in the last quarter 
of NUP153C yielded a protein greatly deficient for binding to HIV-1 CAN (Figure 3-7). 
Because the tetra-alanine 1415-FTFG-1418 NUP153C mutant protein was significantly 
defective for binding assembled CA-NC tubes, we infer that this specific FG motif is 
important for NUP153C binding to multimerized CA. 
We believe our results reflect the nature of the NUP153C-CA interaction during 
HIV-1 infection. Unlike a bimolecular interaction between two well-folded domains, 
each with a single binding site, NUP153C exhibits no appreciable secondary structure and 
is highly repetitive in its primary sequence, particularly for phenylalanine-based FG 
motifs. As FG sequences appear to dictate NUP153C binding to CAN, each of the 29 
motifs may possess some affinity for CAN. Residues adjacent to the phenylalanine, such 
as glycine, may allow proper flexibility to fit into the helix 3/4 pocket for Asn57 
engagement. We envision that residues peripheral to the motif may also contribute intra- 
and inter-molecular interactions. This interpretation is consistent with the mode of CPSF6 
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binding: the CPSF6 FG dipeptide (residues Phe321 and Gly322) is critical for CPSF6358 
mediated restriction [240], while upstream residues Val314 and Leu315 fulfill important 
secondary roles through engaging additional hydrophobic patches located between CAN α 
helices 4 and 5. CPSF6 backbone functional groups also interact to varying degrees with 
the side-chains of CA residues Asn74, Thr107, Lys70, and Gln67 [234] (Figure 3-10C). 
Given this model, we hypothesize that differential accessibility of the CAN helix 
3/4 pocket might factor into the contrasting binding specificities observed between 
monomeric and oligomerized CA: while the pocket is likely exposed as a soluble NTD 
fragment in the pull-down assay, it may be less available within the context of a 
multimeric CA array. The CTD of the adjacent CA subunit covers the bottom edge of the 
cavity (Figure 3-16A), and the interacting NUP153C peptide would need to reach into the 
crevice between CA subunits, past the cyclophilin-binding loop, and under helix 5 to 
reach the pocket (Figure 3-16B). These steric requirements likely limit the number of 
NUP153C FG motifs capable of forming energetically favorable interactions with the 
oligomerized CA array present on the viral core. 
 
Association with core uncoating and sensitivity to cell cycle arrest 
 Accordingly, alterations in the rate or extent of CA core uncoating may alter 
engagement of NUP153 during infection. Though both Trim-NUP153C and Trim-
CPSF6358 presumably encounter CA cores shortly after entry (Figure 3-3) [240], Trim-
CPSF6358 restricted the hyperstable CA mutant viruses E45A and Q63A/Q67A 
[45,57,119,120,249] as efficiently as WT cores, while Trim-NUP153C was less effective 
at restricting either of these mutants. Both mutant CAN proteins in large part retained  
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Figure 3-16. Location of NUP153C binding site within multimerized CA. (A) Model of the 
HIV-1 CA hexamer (pdb: 3j34) [43], with surface representations of two adjacent CA units 
shown. Side chains involved in NUP153C binding are shown as sticks and labeled, with the 
binding pocket highlighted by a dashed white circle. (B) Model of the HIV-1 inter-hexameric CA 
interface (pdb: 3j34). The two molecules in panel A were rotated 90º around the y-axis, -10º 
around the x-axis, and juxtaposed with two CA molecules from the adjacent hexamer. The z-
plane was clipped to expose the NUP153C binding site within the interface. 
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NUP153C binding in vitro, suggesting that some CA disassembly may be needed for 
interaction with NUP153C within cells. 
 These hyperstable CA mutant viruses acutely depend on the cycling state of the 
cell. Comparison between cell cycle dependence and NUP153 reliance resulted in a 
strong negative correlation within the panel of CA mutant viruses (Figure 3-14D). This 
correlation was stronger than the relationship between CPSF6358 sensitivity and cell cycle 
dependence (Figure 3-14F), suggesting a more direct association with NUP153 
engagement. Consistent with this, CPSF6 binding mutant virus N74D was cell cycle 
independent, while N57A and N57D mutant viruses, both of which are also defective for 
NUP153 binding, were sensitive. While the direct cause of cell cycle dependence is not 
clear, we suspect that defective NUP153 binding is a key contributor, and that hyper-
stable CA cores may phenotypically mimic this effect. 
 
Competitors of NUP153-CA binding 
The HIV-1 CA side-chains involved in NUP153C binding overlap those identified 
to interact with CPSF6. Accordingly, we found recombinant NUP153C able to compete 
with CPSF6 for binding to HIV-1 CAN in vitro (Figure 3-10D). The overlapping binding 
sites suggest these proteins may take interdependent or even antagonistic roles during 
infection. While the role of endogenous CPSF6 protein in HIV-1 infection is unknown, 
the cytoplasmic CPSF6358 truncation variant potently restricts HIV-1 
[66,177,234,240,250]. Like Trim-NUP153C, CPSF6358 likely interacts with the viral core 
shortly after entry; both a Trim-fusion protein containing the CPSF6 binding domain 
[240], and the cytoplasmically expressed CPSF6375 isoform [251], yield proteins capable 
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of preventing the completion of reverse transcription. Interestingly, CPSF6358 does not 
inhibit reverse transcription, but instead blocks HIV-1 nuclear import. Additionally, 
CPSF6358 appears to inhibit only a subset of CA mutant cores that it is able to bind [66] 
(Figure 3-11B and 3-11C). This may reflect an incomplete understanding of the 
mechanism of CPSF6358 restriction, which could involve antagonism of the CA-NUP153 
interaction (Figure 3-11D). While CPSF6358-mediated stabilization of the CA core 
[66,250] may contribute to the nuclear import defect, it seems possible that direct 
competition for NUP153 binding may also be at play. 
Small molecules that bind the helix 3/4 pocket in CA may also preclude NUP153 
binding during HIV-1 infection. At least part of the PF74 antiviral mechanism occurs 
before nuclear entry, as it can inhibit HIV-1 reverse transcription [245]. Yet, its altered 
dose-response curve in NUP153 depleted cells suggests that it antagonizes CA 
engagement with NUP153 as well (Figure 3-12). Notably, recently identified 
pyrrolopyrazolone small molecules BI-1 and BI-2 bind the same pocket, yet inhibit HIV-
1 nuclear import [252]. As both PF74 and the pyrrolopyrazolone compounds bind CAN 
with similar affinity [234,252], we speculate that the contrasting phenotypes observed 
with these small molecules is due to their similar abilities to directly compete with host 
factors that bind the helix 3/4 pocket juxtaposed with their differential affects on CA core 
stability: PF74 destabilizes incoming capsids [235], whereas BI-1 and BI-2 can stabilize 
capsid structures in vitro [252]. TNPO3 depletion is proposed to mis-localize endogenous 
CPSF6 into the cytoplasm, recreating the phenotypes conferred by CPSF6358 expression 
[66]. Resembling our observations with NUP153 knockdown cells, infection of TNPO3 
depleted cells exhibited a similar profile of reduced sensitivity to PF74 [253]. 
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Materials and Methods 
 
Plasmid constructs 
Infection assays utilized single-round viruses carrying either GFP or luciferase 
reporter genes. GFP-based constructs included HIV-1, EIAV, BIV, RSV, FIV, MLV, 
HIV-2 strain ROD, simian immunodeficiency viruses SIVmac, SIVagmSab, and 
SIVagmTan, all described previously [96,231]. HIV-1 CA mutations were generated 
through site-directed mutagenesis of the HIV-1NL4-3-based pHP-dI-N/A packaging 
plasmid [217] (AIDS Research and Reference Reagent Program [ARRRP]), which were 
co-transfected with either pHI-vec2.GFP or pHI-Luc transfer vectors [231]. 
Human NUP153 (accession number NM_005124.3), or deletion mutants thereof, 
fused to N-terminal HA tags were expressed from the pIRES-dsRed Express HA-
NUP153 expression vector [231]. Trim-fusion constructs, which were built within 
pLPCX-rhTrim5α-HA [121], were created by engineering a BamHI site at nucleotides 
corresponding to residues 301 and 302 of rhesus Trim5α, and ligating the digested vector 
with sequences encoding HA-NUP153C, NUP153C-HA, or CPSF6358-HA [177]. 
Truncated Trim-HA was engineered by modifying the Trim-HA-NUP153C vector to 
encode two stop codons at the nucleotides corresponding to the first two residues of 
NUP153C. All deletion and missense mutations within animal-cell expressed NUP153C 
were engineered by site-directed-mutagenesis of plasmids pLPCX-Trim-HA-NUP153C or 
pLPCX-HA-NUP153C. 
HIV-1NL4-3 CA carrying C-terminal his and FLAG tags was expressed from the 
pET11a-HIV1-CA-his-flag bacterial expression vector. The vector encoding tagged HIV-
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1 CA NTD (pET11a-HIV1-CAN-his-flag) was constructed by removing nucleotides 
corresponding to CA residues 147-231 from the full-length expression vector. Bacterial 
expression vectors for FIV CA were generated by amplifying DNA encoding full-length 
FIV CA (residues 1-223; pET11a-FIV-CA-his) or NTD only (residues 1-140; pET11a-
FIV-CAN-his) from pFP93 [254] with a primer encoding a C-terminal his-tag, and 
ligating with digested pET11a DNA. pET22b-based bacterial expression vectors 
encoding C-terminally his-tagged N-tropic MLV (pET22b-NMLV-CA-his) and EIAV 
(pET22b-EIAV-CA-his) were obtained from the laboratory of Dr. Joseph Sodroski, and 
CA NTDs were engineered from full-length his-tagged constructs by removing 
nucleotides corresponding to residues 133-263 of N-MLV, and residues 149-231 of 
EIAV, by site-directed mutagenesis. 
A construct encoding an N-terminal GST protein fused to NUP153C (pGEX2T-
GST-NUP153C) was created by deleting sequences encoding residues 1-895 from a 
bacterial expression construct (pGEX2T-hNUP153) encoding the full-length human 
protein [180]. Plasmid pGEX2T-his-GST-pp-NUP153C, which was utilized to obtain tag-
free NUP153C protein, was derived from pGEX2T-GST-NUP153C by sequentially 
engineering a PreScission protease site between GST and NUP153C and then appending a 
his-tag N-terminal to GST. A stop codon was introduced at the nucleotides corresponding 
to residue 1350 to generate the ∆1350-1475 truncation mutant. The 7xFG/A mutant 
NUP153C was engineered for bacterial expression by swapping the WT sequence present 
in pGEX2T-his-GST-pp-NUP153C with a fragment encoding NUP153 residues 1178-
1475 amplified from pLPCX-HA-NUP153C-7xFG/A. All coding sequences were verified 
through DNA sequencing. 
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Cells 
293T and HOS cells were cultured in DMEM (Invitrogen) supplemented with 
10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. HOS cells stably transduced 
with MLV-derived LPCX transfer vectors were subsequently selected and maintained 
with 2 µg/ml puromycin. Approximately 25,000 HOS cells seeded per well of a 24-well 
plate were transfected the next day with a final concentration of 40 nM siNUP153#1 
(GGACTTGTTAGATCTAGTT) or a mismatch control of siNUP153#1, referred to as 
siControl (GGTCTTATTGGAGCTAATT) (Dharmacon) [231], using RNAiMax 
(Invitrogen) according to the manufacturer’s instructions. Dividing or cell cycle arrested 
cells were collected at the time of infection, fixed in 70% ethanol, and incubated for 30 
min at room temperature in staining solution [0.1% Triton X-100, 0.2 mg/ml RNAse A 
(Invitrogen), and 20 µg/ml propidium iodide in phosphate-buffered saline (PBS)]. The 
cells were washed, and cellular DNA content was assessed with a FACSCanto flow 
cytometer (Becton, Dickenson and Company) equipped with FACSDIVA software. 
 
Virus production 
Viral vector particles were produced by transfecting 293T cells in 10-cm plates 
with 10 µg total of various ratios of the aforementioned virus production plasmids using 
CaPO4. The cells were washed 16 h after transfection, and supernatants collected from 24 
to 72 h thereafter were clarified at 300 x g, filtered through 0.45 µm filters (Nalgene), and 
either allotted and frozen or concentrated by ultracentrifugation using an SW32Ti rotor at 
50,000 x g for 2 h at 4°C before freezing. Concentrations of HIV-1 and EIAV CA mutant 
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viral stocks were determined alongside concomitantly produced WT viruses using an 
exogenous 
32
P-based assay for RT activity [222]. 
 
Infectivity assays 
HOS cells (10,000 or 2,500) seeded onto 48-well or 96-well plates, respectively, 
were infected with various reporter viruses. Percentages of GFP-positive cells were 
determined 48 h post-infection (hpi) using a FACSCanto flow cytometer equipped with 
FACSDIVA software. GFP reporter experiments comparing retroviral genera were 
performed with virus inoculates adjusted to yield ~ 40% GFP-positive cells in control 
samples. HIV-1 or EIAV CA mutant viruses (2 x 10
5
 RTcpm) were used to infect 96-well 
and 48-well plates of cells, respectively. HIV to EIAV infectivity ratios were calculated 
after initially normalizing to the average of MLV and FIV negative control viruses to 
account for slight differences in overall infectivities between stable cell lines. 
Cyclosporine (5 µM, Sigma) was introduced to cells at the time of infection. Cell cycle 
arrest experiments were performed by plating 2,500 control or 5,000 experimental cells 
treated with 5 µM Etoposide-phosphate (Calbiochem) the day before infection. 
Quantitative PCR for the accumulation of viral late reverse transcripts and 2-LTR-
containing circles were performed as previously described [231]. The quantitation of 
early reverse transcripts was performed using primers AE989 and AE990 and Taqman 
probe AE995 [255]. 
 
Western blot analysis 
109 
Cells stably expressing Trim-fusion proteins were lysed in Buffer A [25 mM Tris-
HCl pH 7.5, 200 mM NaCl, 1 mM DTT, 1 mM EDTA, Complete protease inhibitor 
(Roche)] and sonicated for 30 s total with a misonix sonicator. Protein concentration of 
the bulk lysate was determined by Bradford assay (Bio-rad), and 75 µg of each sample 
were electrophoresed through Tris-glycine polyacrylamide gels, and transferred onto 
polyvinylidene fluoride membranes. Transiently expressed HA-tagged proteins were 
either extracted with buffer H [10 mM Tris-HCl pH 8.0, 10 mM KCl, 1.5 mM MgCl2] 
followed by repeated freeze-thaws, or Triton buffer [50 mM Triethanolamine, 250 mM 
NaCl, 0.5% Triton X-100], and pelleted in a microcentrifuge for 20 min at 21,000 x g at 
4°C. Stably expressing cells were also fractionated by initial lysis in Buffer F1 [20 mM 
Tris-HCl pH 7.5, 10 mM NaCl, 1.5 mM MgCl2, 0.25 % Triton X-100, and Complete 
Protease Inhibitor], followed by centrifugation at 6,000 x g. The supernatant was 
removed as Fraction 1, and the process was repeated, with the resulting supernatant 
combined with the previous fraction. The subsequent pellet was resuspended in Buffer F2 
[Buffer F1 lacking Triton X-100, but with 0.5% sodium deoxycholate and 1% Tween-
40], and pelleted at 21,000 x g for 15 min. The supernatant was removed as Fraction 2, 
and pellet was resuspended in 1x Turbo DNase buffer and treated with 40 U/ml Turbo 
DNase (Ambion) for 10 min at 37° C. Two parts fraction 1, one part fraction 2, and one 
part of the remaining fraction (Fraction 3) were each mixed with sample loading buffer 
and separated on Tris-glycine polyacrylamide gels. Exogenously expressed HA-tagged 
proteins were detected using a 1:4,000 dilution of HRP-conjugated 3F10 antibody 
(Roche) or 1:4,000 dilution of mouse 16b12 antibody (Covance) and developed with 
ECL prime (GE Healthcare) or Femto (Thermo Scientific) detection reagents. NUP153, 
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NUP62, and NUP358 were detected with a 1:4,000 dilution of mouse monoclonal 
antibody mab414 (Abcam). HRP-conjugated mouse anti-β-actin antibody or mouse anti-
α-tubulin antibody (Abcam) were used at 1:10,000 dilutions to confirm equal lysate 
loading across samples. His-tagged HIV-1 CA was detected with 1:15,000 α-his HRP 
(Clontech). CA-NC protein was detected with 1:5,000 mouse anti-p24 antibody ab9071 
(Abcam). Histone H3 was detected with 1:2,000 rabbit histone H3 antibody #9715 (Cell 
Signaling Technology). All mouse and rabbit primary antibodies were detected using 
1:10,000 dilutions of anti-mouse or anti-rabbit HRP secondary antibodies (Dako). 
 
Immunofluorescence confocal microscopy 
 Cells transduced with empty LPCX vector or stably expressing HA-epitope 
tagged rhTrim5α, NUP153C, or fusion proteins thereof, were cultured on eight-well 
chamber slides. After 24 h, the cells were fixed with 4% paraformaldehyde for 10 min, 
washed, and permeabilized with PBS containing 0.5% Triton X-100. The permeabilized 
cells were blocked with PBS containing 10% FBS for 1 h, and stained with a 1:100 
dilution of anti-HA antibody 16b12. After a 30 min wash with PBS, the cells were 
incubated for 1 h with a 1:1,000 dilution of an Alexa Fluor 555 conjugated goat anti-
mouse IgG antibody (Invitrogen), as well as Hoechst 33342 (Invitrogen) diluted to a 
concentration of 0.2 µg/ml. After an additional 30 min wash with PBS, the samples were 
covered with mounting medium [150 mM NaCl, 25 mM Tris pH 8.0, 0.5% N-propyl 
gallate, and 90% glycerol]. The processed samples were analyzed on a Nikon Eclipse 
spinning disk confocal microscope. 
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NUP153 protein purification 
 GST-NUP153C was expressed in BL21-CodonPlus (DE3)-RILP E. coli (Agilent) 
grown in 2X YT media and induced at an optical density of 0.8 at 600 nm (OD600) with 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 1 h at 18°C. Cells were pelleted at 
6,000 x g, and sonicated for 5 min in buffer A. The lysate was centrifuged for 30 min at 
35,000 x g, and the pellet was resuspended in buffer B [1 M NaCl, 25 mM Tris-HCl pH 
7.5, 1 mM DTT, 1 mM EDTA, Complete protease inhibitor] with a dounce homogenizer. 
The lysate was again spun at 35,000 x g, and the pellet was resuspended in Buffer C [2 M 
Urea, 200 mM NaCl, 25 mM Tris-HCl pH 7.5, 1 mM DTT, 1 mM EDTA, Complete 
protease inhibitor] with a dounce homogenizer. After a last centrifugation at 35,000 x g, 
the supernatant was collected and incubated with glutathione-sepharose beads (GE 
Healthcare) overnight at 4°C. The beads were washed with buffer D [200 mM NaCl, 25 
mM Tris-HCl pH 8.0, 1 mM DTT, 1 mM EDTA, Complete protease inhibitor], and the 
protein was eluted with buffer D containing 20 mM glutathione. Eluted protein was 
dialyzed against buffer D to remove excess glutathione, spin concentrated by 
ultrafiltration through a 10,000 nominal molecular weight limit (NMWL) Amicon filter 
(Millipore), and flash frozen in liquid nitrogen for storage at -80ºC. 
BL21-CodonPlus (DE3)-RILP E. coli transformed with pGEX2T-his-GST-pp-
NUP153C was grown to an OD600 of 0.8, followed by induction with 1 mM IPTG for 1 h 
at 18°C. Cells were pelleted at 6,000 x g, and sonicated for 5 min in buffer A. The lysate 
was then centrifuged for 30 min at 35,000 x g, and the pellet was resuspended in buffer E 
[6 M Urea, 200 mM NaCl, 25 mM Tris-HCl pH 7.5, 1 mM DTT, 1 mM EDTA, 
Complete protease inhibitor] with a dounce homogenizer. The lysate was then 
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centrifuged at 40,000 x g for 1 h, and the resulting supernatant was incubated with Ni-
NTA conjugated agarose beads (Qiagen) overnight. The beads were then initially washed 
with buffer E, and then progressive dilutions of buffer E into cleavage buffer [150 mM 
NaCl, 50 mM Tris-HCl pH 7, 1 mM DTT, 1 mM EDTA] (3:1, 1:1, 1:3), with a final wash 
in cleavage buffer only, each supplemented with 7.5 mM imidazole. The beads were 
incubated with 5 U of PreScission protease (GE Healthcare) for 48 h. The supernatant, 
which was cleared with 0.1 volumes of Ni-NTA beads and glutathione-sepharose beads 
each at 4°C to remove uncleaved protein and residual PreScission protease, was 
centrifuged at 21,000 x g for 15 min at 4°C. The resulting supernatants were quantitated 
following fractionation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and staining with SYPRO Ruby (Invitrogen) or Coomassie blue, as 
compared to a standard curve of bovine serum albumin (BSA), using ChemiDoc MP 
imager (Bio-Rad) with Image Lab software. Cleaved full length NUP153C was recovered 
at ~ 50% purity, with the predominant contaminants degradation products of the full-
length protein, as inferred through comparison with western blots using mab414 
antibody. 
 
CA binding assays 
Recombinant HIV-1 CA-NC was expressed in E. coli, purified, and assembled 
into CA-NC complexes as previously described [40]. Expression constructs encoding 
full-length HA-NUP153 or fragments thereof were transiently transfected into 293T cells 
using X-tremeGENE 9 DNA transfection reagent (Roche). Cells were collected after 48 
h, lysed with successive freeze thaws in buffer H, and clarified by centrifugation at 
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21,000 x g at 4°C. CA-NC complexes were incubated with clarified lysates for 1 h at 
room temperature before ultracentrifugation for 30 min at 100,000 x g through a 50% 
sucrose cushion prepared in PBS. The resulting pellet was resuspended in 1x sample 
loading buffer, and fractionated by SDS-PAGE. Experiments with purified proteins were 
stained with Coomassie blue or SYPRO Ruby, while experiments using a lysate 
component were developed by western blot. Quantification was performed with a 
ChemiDoc MP imager using Image Lab software. 
 His-tagged HIV-1, MLV, EIAV, and FIV capsid proteins, either full length or 
NTD only, were expressed in BL21-CodonPlus (DE3)-RILP E. coli, grown to an OD600 
of 0.6, and induced for 4 h with 1 mM IPTG. Bacteria pelleted by centrifugation were 
resuspended in Buffer A, sonicated, and centrifuged at 30,000 x g for 30 min. The 
supernatants were incubated overnight with Ni-NTA-sepharose beads, eluted with 20 
mM Tris-HCl pH 8.0, 200 mM imidazole elution buffer, and dialyzed into Tris Buffer 
(20 mM Tris-HCl pH 8.0). Dialyzed protein was concentrated by ultrafiltration through a 
10,000 NMWL filter, centrifuged at 21,000 x g, and the resulting soluble protein was 
quantitated by spectrophotometer. 
 Pull-down assays with full-length CA or CAN proteins were performed by mixing 
20 µl reactions with the following final concentrations: 0.02 µl packed volume Ni-NTA 
beads per µl (0.4 µl total), 20 µM CA, 25 mM Tris-HCl pH 8.0, and either 0.5 µM 
purified NUP153C with 0.1% NP-40 and 150 mM NaCl, or 100 µg 293T lysate 
overexpressing HA-tagged NUP153 with 0.25% Triton X-100 and 200 mM NaCl. 
Mixtures were left rocking at room temperature for 1 h after which the samples were 
washed twice in buffer M [25 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.1% NP-40], 
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allowing the beads to settle by gravity, and finally resuspended in 1x sample loading 
buffer. Saturation curves were achieved by mixing 3 µl packed volume Ni-NTA beads 
with 0.5 µM purified WT or mutant NUP153C, 150 mM NaCl, 25 mM Tris-HCl pH 8.0, 
and 0.1% NP-40, with half-log increments of HIV-1 CAN from 2 µM to 200 µM. Both 
bead-bound and supernatant fractions were separated by SDS-PAGE and stained with 
SYPRO Ruby, with the percent of NUP153C protein bound calculated at each 
concentration. The Kd of NUP153C binding was calculated by subtracting nonspecific 
binding to beads and fitting the resulting data-points with a one-site saturation binding 
nonlinear regression using Prism6 software (GraphPad). 
 CPSF6 competition experiments were performed through modification of the CA-
NC protocol. Assembled CA-NC was diluted to a final concentration of 0.8 µM in the 
reaction mixture. WT or mutant NUP153C was added to a final concentration of 4 µM, 
along with 10 µg total 293T extract expressing C-terminally HA-tagged CPSF6, resulting 
in final concentrations of 170 mM NaCl, 75 mM Tris-HCl pH 8.0, and 0.025% Triton X-
100. Mixtures (20 µl) were incubated at room temperature for 20 min, after which they 
were spun over a 30 µl 20% sucrose cushion in a microcentrifuge at 21,000 x g for 20 
min at 4°C. The resulting pellet was resuspended in sample loading buffer and separated 
by SDS-PAGE. Western blotting with p24 antibody indicated ~ 35% of input CA-NC 
was recovered in the pellet. CA-NC co-sedimentation assays with WT or FG mutant 
NUP153C were performed similarly, but were instead centrifuged over a 25% sucrose 
cushion. 
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IN pull-down assay 
His-tagged HIV-1 and FIV IN [96] and GST [256] were expressed and purified as 
previously described. Pull-down of soluble IN was performed as previously described for 
GST-LEDGF326-530 [244], with 0.8 µM of his-tagged HIV-1 or FIV IN incubated with 
0.47 µM GST-NUP153C or control GST pre-bound to glutathione-sepharose beads in PD 
buffer [150 mM NaCl, 25 mM Tris-HCl pH 7.4, 5 mM MgCl2, 5 mM DTT, 0.1% NP-
40]. BSA (5 µg) was included as an additional specificity control. The reaction was 
incubated for 2 h at 4°C, after which the beads were washed 4 times with PD buffer, and 
settled each time for 20 min in the absence of centrifugation. Recovered samples were 
resolved by SDS-PAGE, and stained with Coomassie blue and western blotted with anti-
his antibody. 
 
Statistical analysis 
Dependencies between variables were assessed by Spearman rank correlation 
using Prism6 software. The significances of pair-wise differences were calculated by 
Student’s t-test (two-tailed) using Prism6 software. 
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Chapter 4 
General Discussion 
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Model of NUP153 FG engagement during lentiviral infection 
Current data and the known biology of this protein suggest NUP153 is likely 
important for trafficking the HIV-1 PIC through the nuclear pore and into the nucleus 
[29,82,231] (Figure 4-1). The viral nucleoprotein complex is likely to initially dock to 
the NPC by engaging NUP358 [82,233]. While intact HIV-1 cores are too large to enter 
the central channel, CA cores in various stages of disassembly may enter far enough for 
remaining CA to be accessed by the FG domains present in NUP153C. 
 CA binding with NUP153C may serve two distinct roles during infection. Firstly, 
NUP153 may be responsible for physically translocating the PIC by engaging CA 
molecules that may associate with it. The relatively short half-life of NUP153 at the NPC 
may contribute to the release of the PIC into the nucleoplasm [181]. Secondly, as even a 
partially disassembled core could remain too large to efficiently pass through the NPC 
channel, CA interaction with NUP153 may be required to fully uncoat the viral core at 
the NPC and prime the PIC for nuclear import. Indeed, CA cores have been shown to 
dock to NPCs for several hours before PIC nuclear translocation [80]. CA oligomers may 
interact with a limited subset of NUP153C FG motifs, while increased CA pocket 
accessibility from progressive core disassembly may expose monomeric CA to an 
expanded number of NUP153C FG repeats. While CA mutant viruses such as N74D may 
uncoat differently and circumvent this mechanism without penalty in various transformed 
cell lines, they apparently incur steep costs to infectivity in other cell types, such as 
primary macrophages [233,257]. 
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Figure 4-1. The NUP153-CA interaction during HIV-1 infection. Partially uncoated HIV-1 
cores dock at the NPC through engaging NUP358 (light green). Once docked, NUP153 (dark 
green) FG motifs bind CA through phenylalanine insertion into the hydrophobic pocket of the 
NTD, forming hydrogen bonds with CA residue Asn57, as well as adjacent polar side-chains 
(enlarged to the right). CA engagement with NUP153 is required for HIV-1 nuclear import, either 
directly during PIC translocation, or for completion of a prerequisite uncoating step. Perturbation 
of NUP153 engagement may affect multiple steps, such as intranuclear trafficking and integration 
site selection [231,248,258]. 
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Convergence in NUP153 use amongst viral families 
Divergent viruses have adapted to use NUP153 for their own devices. Our results 
suggest EIAV, which presents different amino acid residues flanking the CAN 
hydrophobic pocket, may have either retained, or convergently evolved NUP153 binding. 
Hepatitis B virus (HBV) has also been reported to bind NUP153 during its nuclear 
transport; though the HBV core is sufficiently small to traverse the NPC channel, 
NUP153 binding is believed to be important for HBV core conformational change and 
genome release within the nuclear basket [200]. This interaction may also require binding 
to NUP153 FG motifs, as both of the broadly defined regions mapped for HBV capsid 
binding overlapped parts of NUP153C. The S. pombe homolog of NUP153, Nup124p, is 
important for Tf1 retrotransposition and binds the Tf1 Gag protein, though binding did 
not necessarily appear to map to Nup124p FG motifs [197,259]. Perhaps akin to effects 
caused by differential HIV-1 uncoating, the requirement for Nup124p appears to be 
related to the state of Tf1 Gag multimerization [199]. 
It remains to be determined whether FG motifs found on additional nucleoporins 
may bind HIV-1 and aid its infection. While the effects of NUP98 depletion on HIV-1 
infection are relatively modest [175,177,248], this protein can also co-sediment with 
HIV-1 CA-NC tubes in vitro [248]. Similarly, the GLFG-motif enriched domain of S. 
cerevisiae NUP100, predicted to be orthologous to vertebrate NUP98, binds Ty3 Gag 
protein [260]. Alternatively, while CA binding with the CHD is proposed to determine 
the requirement for NUP358 [233], it remains to be seen whether its own FG domains 
may bind CA and contribute to its function during infection [261]. While numerous FG 
nucleoporins exist, it is likely that certain characteristics specific to NUP153, including 
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its length, flexibility, and its relatively high dissociation rate from the NPC, along with its 
spatial location around the nuclear rim of the NPC, makes this protein particularly 
important for lentiviral passage through the nuclear pore. 
 
Interdependence of CA-determined host factors during infection 
A number of phenotypic similarities suggest the roles of TNPO3, NUP153, 
NUP358, CPSF6, and CypA during HIV-1 infection are interrelated. CA mutant virus 
N57A is NUP153 and CPSF6 binding-defective but detectably binds the NUP358 CHD, 
yet does not require NUP358 expression for infection. Perhaps most starkly, the N74D 
CA mutant virus is insensitive to knockdown of TNPO3, NUP153, and NUP358, despite 
possessing a CA protein capable of binding all three proteins with similar affinities to 
WT CA (Figure 3-8 and [233]). As the N74D mutation clearly counteracts CPSF6 
binding [177,234], it seems plausible that CPSF6 engagement licenses HIV-1 to employ 
NUP358 and NUP153 during infection. CPSF6 is currently believed to be exclusively 
nuclear at steady state, suggesting that it may not exert its effects on HIV-1 until the virus 
engages the NPC. Curiously, siRNA depletion of CPSF6 does not affect HIV-1 infection 
[177]. 
CypA also appears to alter nuclear transport factor dependence during HIV-1 
infection. The CypA and NUP358 CHD binding mutants G89V and P90A are 
comparably less sensitive to NUP153 depletion and CPSF6358 restriction than WT virus 
[66,231,233]. Consistent with this, abrogation of CA binding with CypA, either through 
CypA depletion or competition with the small molecule cyclosporine, rescued viruses 
inhibited by NUP153 or NUP358 knockdown [231,233]. While cyclosporine treatment 
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can partially rescue WT HIV-1 infection in TNPO3 depleted cells [233,253], the lack of 
complete rescue may reflect its multiple potential roles in promoting HIV-1 infection. 
CypA binding to HIV-1 CA can alter its disassembly [191], suggesting that its effect on 
NUP153, NUP358, and TNPO3 may be indirect through modulating the rate and extent 
of CA core uncoating. 
 
Effects of nuclear transport proteins on integration site selection 
While HIV-1 appears to predominantly utilize NUP153, NUP358, and TNPO3 to 
affect its import into the nucleus, these factors can also affect post-nuclear trafficking as 
evidenced by differences in HIV-1 integration site distributions upon factor knockdown. 
Numerous different forces can influence integration site distribution. IN favors certain 
nucleotide patterns at the site of integration [262,263]. Integration also favors the 
distorted major grooves that occur when DNA is wrapped around the nucleosome core 
[264,265], as well as certain epigenetic modifications [265]. Lens epithelium-derived 
growth factor (LEDGF)/p75, which is a lentiviral IN-binding cofactor, in large part 
dictates integration along active transcriptional units [255,266,267]. Interestingly, 
TNPO3, NUP358, and NUP153 appear to contribute to an even broader level of 
integration site preference [68]: depletion of TNPO3, NUP358, and to a lesser extent, 
NUP153, reduced the extent of integration in gene dense regions of chromatin 
[233,248,258,268]. This pattern was consistent with the involvement of CA, as the HIV-1 
chimeric virus encoding MLV CA, as well as CA missense mutants N57A and N74D, 
showed a similar shift in integration site distribution [233,258,268]. Notably, CypA 
binding was also found to affect integration site selection, as disruption of CypA binding 
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to CA by cyclosporine treatment resulted in an increase in the number of integration 
events in chromosomal regions enriched in transcriptional units [233]. 
It is possible that these proteins are directly involved in directing the PIC to 
distinct regions of chromatin; NUP153 has been shown to associate with large regions of 
active chromatin in drosophila [205], and TNPO3 may engage the HIV-1 intasome to 
effect integration [94]. On the other hand, NUP358 appears more important for 
integration targeting than NUP153, yet this protein does not appear to be found within the 
nucleus during interphase [150]. Furthermore, depletion of a number of other nuclear host 
proteins including IK, ANAPC2, WDHD1, SNW1, and PRPF38A similarly redirected 
integration away from gene  dense chromosome regions [268]. It remains formally 
possible that the roles of some host factors in dictating integration to these regions may 
be indirect, instilled through alteration of global chromosomal environment as compared 
to specific affects on HIV-1 PIC trafficking. Still, ablation of gene dense region targeting 
by CA mutations such as N74D highlights a specific role for CA in post-nuclear PIC 
trafficking. The mechanism of nuclear import may be linked with integration site 
targeting by affecting the chromosomal environments first encountered by the PIC upon 
nuclear entry. 
 
Model of CA and nuclear transport factors during HIV-1 nuclear entry 
We propose the following working model to coalesce recently reported results 
from the rapidly evolving field of HIV-1 PIC nuclear transport (Figure 4-2). While the 
initial steps of uncoating likely occur shortly after entry [45], the final events of 
uncoating may occur at the NPC [80]. The partially uncoated PIC likely docks at the NPC  
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Figure 4-2. Model of the potential roles of the CA-dependent nuclear transport factors 
during HIV-1 infection. NUP358, NUP153, and CPSF6 at the nuclear pore likely act on PIC-
associated CA to aid HIV-1 infection. TNPO3 is required to localize CPSF6 to the nucleus; 
premature cytoplasmic CPSF6 binding to CA can prevent nuclear import. TNPO3 may affect 
integration by interacting with IN within the nucleus. CypA modulates CA uncoating, altering 
dependencies on NUP358, NUP153, and TNPO3. Perturbation of this pathway by CA mutation 
or TNPO3, NUP153, or NUP358 knockdown results in altered integration site selection away 
from gene-dense regions of chromatin. 
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by engaging the NUP358 CHD with its remaining CA proteins [82,233]. Once docked, 
CPSF6 and NUP153 then engage the PIC. The combined actions of these proteins are 
necessary for PIC nuclear import. TNPO3 expression is required for proper nuclear 
localization of CPSF6; CPSF6 binding to CA cores too early during infection 
misregulates the upstream steps of uncoating [66,250] and NPC engagement, blocking 
infection at the step of nuclear import. TNPO3 may also have an additional intra-nuclear 
role permitting proper nuclear trafficking and integration, perhaps related to its 
interaction with IN. These concerted steps of uncoating and nuclear import appear to 
influence the downstream steps of nuclear trafficking and integration. It will be 
instructive to see if CPSF6 depletion similarly influences HIV-1 integration site 
distribution. 
The precise mechanistic requirements for NUP358, NUP153, and CPSF6 for 
nuclear import remain unclear: these proteins may be critical for a prerequisite uncoating 
step prior to nuclear import, or they may be directly involved in the act of PIC nuclear 
translocation. As these three proteins have each been published to bind CA, the latter 
model presupposes that CA would need to be concomitantly imported into the nucleus 
with the PIC. This point remains highly controversial; CA has historically been 
noticeably absent from the nucleus, with only a couple recent reports observing potential 
PIC-associated CA signals within the nuclear fraction [81,82]. Notably, TNPO3, 
NUP358, and NUP153 are not absolutely required for HIV-1 infection of transformed 
cell lines: while the WT virus is highly dependent on these factors, certain CA mutant 
viruses such as N74D can bypass CPSF6 binding and infect cells depleted for NUP358, 
NUP153, or TNPO3 without a concomitant loss of infectivity. While the N74D CA 
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mutant virus was previously proposed to bypass these requirements by relying on an 
alternative set of NUPs (including NUP155 and NUP98) [177], it is not clear whether 
these proteins indeed fulfill critical roles for N74D mutant virus infection [248]. 
Alternatively, if the main function of these nuclear transport factors is to uncoat 
the PIC as a prelude for nuclear import, then alterations to viral uncoating may obviate 
the need for this mechanism during infection. CypA modulates HIV-1 core stability 
[191], and is accordingly capable of modulating the viral requirement on NUP153 and the 
other nuclear transport factors [231,233,253]. While a mechanism for active PIC nuclear 
transport would be required in all cell types, optimal CA uncoating may be particularly 
important in certain cell types, such as macrophages. Indeed, the N74D CA mutant virus 
exhibits a significant infectivity defect in monocyte-derived macrophages [233,257], 
where its reverse transcription is defective [257]. Because Asn74 is highly conserved 
among primate lentiviruses, HIV-1 may very well rely on these nuclear transport factors 
in vivo [177]. 
Curiously, while HIV-1 appears to rely upon NUP358, NUP153, TNPO3, and 
CPSF6 during infection, other lentiviruses only appear to share certain aspects of this 
mechanism. SIVmac does not bind NUP358, and accordingly does not rely on this 
protein for infection. Furthermore, EIAV utilizes NUP153 and TNPO3, though it does so 
in the apparent absence of CPSF6 binding. FIV likely utilizes an entirely different 
mechanism, as it does not seem to require any of these factors. Thus, although recent 
years have witnessed significant advances on the role of CA and particular nuclear 
transport proteins in HIV-1 PIC nuclear import, there is clearly much left to learn about 
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how HIV-1 and some of the other lentiviruses circumvent the nuclear envelope to reach 
their chromosomal targets of integration. 
 
Concluding remarks 
 Despite two decades of research, the identities of the critical molecular 
interactions between viral and host proteins governing HIV-1 nuclear import has 
remained elusive. We find the CA proteins of HIV-1 and a subset of other lentiviruses 
directly bind NUP153, a major functional component of the nuclear pore complex. 
Determinents of CA interaction with the NUP153 FG motifs correlate well with the viral 
requirement for this nucleoporin during infection. Specific FG motifs within NUP153 
were necessary for the interaction, highlighting a mechanism wherein certain lentiviral 
capsids have likely evolved to recognize the unique biophysical properties of the nuclear 
pore. Our findings demonstrate a key facet of lentiviral nuclear entry, and posit 
comparable mechanisms to occur across viruses and viral elements that require entry into 
the host nucleus.
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